CONFIDENTIA L
209611
1Protocol Title: A Phase I, Double -Blind, Two- Part, Sequential Study  to Evaluate the 
Pharmacokinetics of Gepotidacin Tablets in Healthy  Adult and Adolescent Participants
Protocol Number: 209611
Compound Number: [COMPANY_004]2140944
Study Phase: Phase I
Short Title :Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents
Sponsor Name [CONTACT_29560]: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_326865] Inf ormation :Please refer to the Study  Reference 
Manual
Regulatory Agency Identifying Number: IND: 111885
Approval Date: 13- JUN -2019
Copy right 2019 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this information is prohibited. 2019N401436_00
GlaxoSmithKline group of companies
TITLE PA GE2019N422403_00
 2019N422403_00
[COMPANY_003]
[COMPANY_003]
2019N401436_00 CONFIDENTIA L
2096 11
3TABLE OF CONTENTS
PAGE
1.PROTOCOL SUMMARY .......................................................................................... 6
1.1. Synopsis ....................................................................................................... 6
1.2. Schema ...................................................................................................... 10
1.3. Schedule of Activities (SoA) ........................................................................ 11
2.INTRODUCTION .................................................................................................... 22
2.1. Study Rationale .......................................................................................... 22
2.2. Background ................................................................................................ 22
2.3. Benefit/Risk Assessment ............................................................................ 23
2.3.1. Risk Assessment ......................................................................... 24
2.3.2. Benefit Assessment ..................................................................... 27
2.3.3. Overall Benefit: Risk Conclusion .................................................. 27
3.OBJECTIVES AND ENDPO INTS ........................................................................... 27
4.STUDY DESIGN .................................................................................................... 28
4.1. Overall Design ............................................................................................ 28
4.2. Scientific Rationale for Study Design .......................................................... 29
4.3. Justification for Dose .................................................................................. 30
4.4. End of Study Definition ............................................................................... 30
5.STUDY POPULATION ........................................................................................... 31
5.1. Inclusion Criteria ......................................................................................... 31
5.2. Exclusion Criteria ........................................................................................ 32
5.3. Lifestyle Considerations .............................................................................. 34
5.3.1. Meals and Dietary Restrictions .................................................... 34
5.3.2. Caffeine, Alcohol, and Tobacco ................................................... 34
5.3.3. Activity ......................................................................................... 35
5.4. Screen Failures ........................................................................................... 35
6. STUDY INTERVENTION ........................................................................................ 35
6.1. Study Interventions Administered ............................................................... 36
6.2. Preparation/Handling/Storage/Accountability .............................................. 37
6.3. Measures to Minimize Bias: Randomization and Blinding ........................... 37
6.4. Study Intervention Compliance ................................................................... 38
6.5. Concomitant Therapy .................................................................................. 39
6.6. Dose Modification ....................................................................................... 39
6.7. Intervention after the End of the Study ........................................................ 39
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATIO N/WITHDRAW AL..................................................................... 39
7.1. Discontinuation of Study Intervention .......................................................... 39
7.1.1. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................................ 40
7.1.2. QTc Stoppi[INVESTIGATOR_2121] .................................................................. 40
7.1.3. Gastrointestinal Evaluation Criteria .............................................. 41
7.1.4. Rash/Hypersensitivity Evaluation Criteria ..................................... 41
7.2. Participant Discontinuation/W ithdrawal from the Study ............................... [ADDRESS_326866] to Follow Up ........................................................................................ 42 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
48.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 42
8.1. Efficacy Assessments ................................................................................. 43
8.2. Safety Assessments ................................................................................... 43
8.2.1. Physical Examinations ................................................................ .43
8.2.2. Vital Signs .................................................................................... 43
8.2.3. Electrocardiograms ...................................................................... 43
8.2.4. Clinical Safety Laboratory Assessments ...................................... 44
8.3. Adverse Events and Serious Adver se Events ............................................. 44
8.3.1. Time Period and Frequency for Collecting AE and SAE 
Information ................................................................................... 44
8.3.2. Method of Detecting AEs and SAEs ............................................. 45
8.3.3. Follow -up of AEs and SAEs ......................................................... 45
8.3.4. Regulatory Reporting Requirements for SAEs ............................. 45
8.3.5. Pregnancy ................................................................................... 46
8.4. Treatment of Overdose ............................................................................... 46
8.5. Pharmacokinetics ....................................................................................... 46
8.6. Pharmacodynamics .................................................................................... 47
8.7. Genetics ..................................................................................................... 47
8.8. Biomarkers ................................................................................................ .47
8.9. Medical Resource Utilization and Health Economics .................................. 47
9.STAT ISTICAL CONSIDERATIO NS........................................................................ 47
9.1. Statistical Hypotheses ................................................................................. 47
9.2. Sample Size Determination ........................................................................ 47
9.3. Populations for Analyses ............................................................................ 48
9.4. Statistical Analyses ..................................................................................... 48
9.4.1. Pharmacokinetic Analyses ........................................................... 48
9.4.2. Safety Analyses ........................................................................... 50
9.4.3. Other Analyses ............................................................................ 50
9.5. Interim Analyses ......................................................................................... 50
10.SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS ............................................................................................... 51
10.1. Appendix 1: Abbreviations and Trademarks ................................................ 51
10.2. Appendix 2: Clinical Laboratory Tests ......................................................... 53
10.3. Appendix 3: Regulatory, Ethical, and Study Oversight 
Considerations ............................................................................................ 55
10.3.1. Regulatory and Ethical Considerations ........................................ 55
10.3.2. Financial Disclosure ..................................................................... 55
10.3.3. Informed Consent/Assent Process ............................................... 56
10.3.4. Data Protection ............................................................................ 56
10.3.5. Publication Policy ......................................................................... 57
10.3.6. Dissemination of Clinical Study Data ........................................... 57
10.3.7. Data Quality Assurance ............................................................... 57
10.3.8. Source Documents ...................................................................... 58
10.3.9. Study and Site Closure ................................................................ 58
10.4. Appendix 4: Adverse Events: Definitions and Procedures for 
Recordi ng, Evaluating, Follow -up, and Reporting ....................................... 60
10.4.1. Definition of AE ............................................................................ 60
10.4.2. Definition of SAE .......................................................................... 61
10.4.3. Recording and Follow -Up of AE and SAE .................................... 62
10.4.4. Reporting of SAE to [COMPANY_004] ............................................................. 64 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
510.5. Appendix 5: Contraceptive Guidance and Collection of Pregnancy 
Information .................................................................................................. 66
10.5.1. Definitions: ................................................................................... 66
10.5.2. Contrace ption Guidance: ............................................................. 67
10.5.3. Collection of Pregnancy Information: ........................................... 68
10.6. Appendix 6: Liver Safety: Required Actions and Follow -up 
Assessments .............................................................................................. 70
10.7. Appendix 7: Clostr idium difficile Testing Procedure and Algorithm .............. 72
10.8. Appendix 8: Division of Microbiology and Infectious Diseases Adult 
Toxicity Tables for Adverse Event Assessment ........................................... 73
11.REFERENCES ....................................................................................................... 80 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
61. PROTOCOL SUMMA RY
1.1. Synopsis
Protocol Title: A Phase I, Double -Blind, Two- Part, Sequential Study  to Evaluate the 
Pharmacokinetics of Gepotidacin Tablets in Healthy  Adult and Adolescent Participants
Short Title :Pharmacokinetics of Gepot idacin Tablets in Adults and Adolescents
Rationale: Single oral doses of gepotidacin (1500 and 3000 mg) were given to patients 
with gonorrhea in a completed Phase IIstudy ,andboth doses achieved >95% efficacy ; 
however, in vitro data and pharmacokinetic ( PK)/pharmacod ynamic modeling revealed 
that a higher dose would prevent the development of resistance and cover organisms with 
higher minimum inhibitory  concentration (MIC).
The selected total daily  dose for gonorrhea is 6000 mg delivered as two 3000 mg dos es 
given either 6or 12hours apart in order to keep Cmax under a threshold of 14 µg/mL  to 
mitigate the occurrence of adverse events (AEs) due to acet ylcholinesterase (AChE) 
inhibition (mild and transient AEs of increased salivation, blurred vision ,and sl urred 
speech were observed following high intravenous [ IV]doses as a 1 or 2 hour infusion 
during a previous stud y).
Although total daily oral [ADDRESS_326867] been given to healthy participants and 
patients as 2000 mg three times daily  (TID) for up to 1 4 day s and daily  IV 4500 mg 
(equivalent to 9783 mg oral dose and based on absolute bioavailability  of46%) doses 
have been given to healthy participants as TID regimen for up to [ADDRESS_326868] not been characterized 
previously  and gepotidacin has not been administered previousl y to adolescents. 
Therefore, this study  will support in clusion of adolescents with a bod y weight ≥40 kg in 
future Phase IIIstudies and will provide the safet y and PK data of two 3000 mg doses 
separated b y the selected dose intervals in Part 1 and Part 2 .
Objectives and Endpoints:
Objectives Endpoints
Primary
Part 1
To evaluate the pharmacokinetics of a 
single 1500 -mg dose and two3000 -mg 
doses of gepotidacin given 6 and
12hoursapart in adult participants1500 mg Single Dose
 Plasma gepotidacin AUC(0-t), AUC(0-∞ ), 
AUC(0 -24), AUC(0 -48), and Cmax, as data 
permit
3000 mg Two Doses
 Plasma gepotidacin AUC(0-t), AUC(0- τ), 
AUC(0 -24), AUC(0 -48), Ro (accumulation 
ratio), and Cmax, as data permit 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
7Objectives Endpoints
Part 2
To evaluate the pharmacokinetics of a 
single 1500 -mg dose andtwo 3000 -mg 
dose sof gepotidacin given at a dosing 
interval (to be determined) in 
adolescent participants1500 mg Single Dose
 Plasma gepotidacin AUC(0 -t), AUC(0- ∞), 
AUC(0 -24), AUC(0 -48), and Cmax, as data 
permit
3000 mg Two Doses
 Plasma gepotidacin AUC(0-t), AUC(0- τ), 
AUC(0 -24), AUC(0 -48), Ro (accumulation 
ratio), and Cmax, as data permit
Parts 1 and 2
To assess the safety of gepotidacin in 
adult participants and adolescent 
participantsAdverse events, clinical laboratory tests, 
vital signs (systolic and diastolic blood 
pressure and heart rate) , and 12-lead 
electrocardiogram readings
Secondary
Part 1
To assess the urine pharmacokinetics
of gepotidacin following a single 
1500 -mg dose andtwo3000 -mg doses 
of gepotidacin given 6 and 12hours 
apart in adult participants Urine endpoints include A etotal, Ae(t1 -t2), 
AUC(0 -τ), AUC(0 -24), AUC(0 -48), fe%, 
and CLr of gepotidacin, as data permit
Part 2
To assess the urine pharmacokinetics
of gepotidacin following a single 
1500 -mg dose andtwo 3000 -mg doses 
of gepotidacin given at a dosing interval 
(to be determ ined) in adolescent 
participants Urine endpoints include A etotal, Ae(t1 -t2), 
AUC(0 -τ), AUC(0 -24), AUC(0 -48), fe%, 
and CLr of gepotidacin, as data permit
Parts 1 and 2
To assess the plasma 
pharmacokinetics of gepotidacin Plasma gepotidacin Tmax, tlag, a nd t1/2, 
as data permit
Overall Design: This is a Phase I, double -blind, single- center, randomized, sequential, 
two-part stud y. Part 1 is being conducted to evaluate the PKof the gepotidacin tablet sin 
healthy  adult participants. Part 2 will evaluate the PK of the gepotidacin tablets in healthy  
adolescent participants. 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
8Part 1: Pharmacokinetics in Healthy Adult Participants
Part 1 is a 3 -period, fixed -sequence stud y that will assess the PK of a single 1500- mg 
dose ( Period 1) and two 3000 -mg dose s of gepot idacin at Hours 0 and 12 (Period 2) and 
Hours 0 and 6 (Period 3) in healthy  adult participants. 
Participants will be randomly  assigned to receive either all active treatment (gepotidacin) 
or placebo for all 3 periods. Approximately  17 participants will be randomized (in a 
14:3ratio) to receive a single dose of gepotidacin 1500 mg (Treatment A) or matching 
placebo (Treatment B) in Period 1 ,gepotidacin 3000 mg separated b y 12 hours 
(Treatment C) or matching placebo (Treatment D) in Period 2, and gepotidaci n 3000 mg 
separated b y 6hours (Treatment E) or matching placebo (Treatment F) in Period 3 to 
obtain 12 evaluable participants on active treatment and 2 evaluable participants on 
placebo.
Participants will participate in 3 treatment periods ,and blood and urine samples will be 
collected for PK anal ysis of gepotidacin concentrations up to 48 to 60 hours after dosing.
This will be a two- part study  in which the PK andsafet y data will be reviewed after 
completion of Part 1 before enrolling participants into Pa rt 2. The dosing interval in 
Part2, Period 2 will be based on the PK, safet y, and tolerability data from Part 1.
Part 2: Pharmacokinetics in Healthy Adolescent Participants
Part 2 is a 2 -period, fixed sequence study  that will assess the PK of a single 150 0-mg 
dose (Period 1) of gepotidacin and two 3000 -mg dose s(Period 2) of gepotidacin in 
healthy  adolescent participants. The two 3000- mg dose swill be separated by  a time 
interval that will be determined based on data from Part 1. The number of PK samples 
and the PK sampling time points may  be modified based on the adult PK data from 
Part1.
Participants will be randomly  assigned to receive either all active treatment (gepotidacin) 
or placebo for both periods. Approximately  17 participants will be randomized (in a 
14:3ratio) to receive a single dose of gepotidacin 1500 mg (Treatment A) or matching 
placebo (Treatment B) in Period 1, and gepotidacin 3000 mg (Treatment G) or matching 
placebo (Treatment H) in Period 2 to obtain 12 evaluable participants on activ e treatment 
and 2 evaluable participants on placebo .
The interval for the two 3000-mg doses in Period 2 will be between 6hours and 12hours 
based on the PK and safety  results from Part 1.
For Part 2 onl y, there may be a 7- day interval between doses in Per iod 1 and Period 2 to 
accommodate the adolescent population school schedule. Treatment Period 1 and 
Treatment Period 2 may  be separated by  [CONTACT_23818] 10 day s.
Participants will participate in 2 treatment periods and blood and urine samples will be 
collec ted for PK anal ysis of gepotidacin concentrations up to 48 hours after dosing. 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
9Disclosure Statement :This is a sequential clinical pharmacology study  that is masking 
the participant and investigator to assigned treatment . 
Number of Participants: Approxima tely 17adult participants willbe randomly  assigned 
to study  intervention in Part 1 to ensure 12 evaluable participants on study  drug with 
evaluable primary  PK parameters and 2 participants on placebo with evaluable safet y 
measurements . In Part 2, approxi mately  17adolescent participants willbe randomly  
assigned to stud y intervention to ensure 12 evaluable participants on study  drug with 
evaluable primary  PK parameters and 2 participants on placebo with evaluable safet y 
measurements .
Intervention Groups and Duration: The treatments will be as follows:
Part 1 -Adult Participants
Treatment A: Single dose 1500 mg (Period 1)
Treatment B: Matching placebo (Period 1)
Treatment C: Two 3000 mg dose s given at Hour 0 and Hour 12 (Period 2)
Treatment D: Two m atching placebo doses given at Hour 0 and Hour 12
(Period 2)
Treatment E: Two 3000 mg dose sgiven at Hour 0 and Hour 6 (Period 3)
Treatment F: Two m atching placebo doses given at Hour 0 and Hour 6
(Period 3)
Note: All d oses will be taken after a standard meal .
Part 2 -Adolescent Participants
Treatment A: Single dose 1500 mg (Period 1)
Treatment B: Matching placebo (Period 1)
Treatment G : Two 3000 mg doses (Period 2; exact dosing interval to be 
determined after Part 1 is complete)
Treatment H : Two matching placebo doses ( Period 2; exact dosing interval to be 
determined after Part 1 is complete)
Note: All doses will be taken after a standard meal.
The duration of the stud y, including Screening, is approximately 47days for Part 1, and 
52days for Part 2.
Data Monitoring Committee: No 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
101.2. Schema
A summary  of the overall study  design is presented in Figure 1.
Figure 1 Study  Design Schematic
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
111.3. Schedule of A ctivities (SoA )
Table 1 Screening Visit -Parts 1 and 2
Procedure Screening (up to 28 days before Day -1)
Outpatient visit X
Informed consent /assent X
Inclusion and exclusion criteria X
Demography X
Full physical examination including height and weight1 X
Laboratory assessments (hematology, chemistry, urinalysis ) X
12-lead electrocardiogram X
Vital sign measurements2 X
Medication/drug/alcohol history X
Past and current medical conditions  X
Serum pregnancy test X
Follicle- stimulating hormone (as needed, to confirm postmenopausal 
status ; Part 1 only )X
Drug, alcohol, and cotinine screen X
HIV, Hepatitis B and C screening X
Serious adverse event review X
HIV = human immunodeficiency virus .
1 A full physical examination will include at a minimum, assessments of the skin, cardiovascular , respi[INVESTIGATOR_696], 
gastrointestinal, and neurological systems.
2 Respi[INVESTIGATOR_268660] . 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
12Table 2 Schedule of A ctivities -Part 1 (Adult Participants)
Procedure1Check
-inTreatment Period 1
(Days)Treatment Period 2
(Days)Treatment Period 3
(Days)Follow -up 
(7[±3] days 
after last 
dose ) or 
Early 
TerminationNotes
–[ADDRESS_326869] (if WOCBP), 
as appropriate 
(see Table 10)
Drug,alcohol , and 
cotinine screenX See Table 10
Laboratory 
assessmentsX X X X XIncluding serum 
chemistry, 
hematology, and 
urinalysis (see 
Appendix 2)
12-lead ECG3 X X X X X X X X X X XSee Table 3 , 
Table 4 , and 
Table 5 for 
timing of 
assessments 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
13Procedure1Check
-inTreatment Period 1
(Days)Treatment Period 2
(Days)Treatment Period 3
(Days)Follow -up 
(7[±3] days 
after last 
dose ) or 
Early 
TerminationNotes
–1 1 2 3 4 5 6 7 8 9 10 11
ECG Holter
monitoring4X X X X X X X X XSee Table 3 , 
Table 4 , and 
Table 5 for 
timing of 
assessments
Vital signs X X X X X X X X X X XSee Table 3 , 
Table 4 , and 
Table 5 for 
timing of 
assessments
Study intervention X X XSee Table 3 , 
Table 4 , and 
Table 5 for time 
points
Blood collection for 
pharmacokineticsX X X X X X X X XSee Table 3 , 
Table 4 , and 
Table 5 for time 
points
Urine collection for 
pharmacokineticsX X X X X X X X XSee Table 3 , 
Table 4 , and 
Table 5 for time 
points
AE/SAE review X================================================================================= == X
Concomitant 
medication reviewX==================================================================== ===============  X 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
14AE = adverse ev ent, ECG = electrocardiogram, SAE = serious AE; WOCBP =wom an of childbearing potential.
1 When coinciding with safety and/or pharmacokinetic assessments, ECGs , vital signs, and pharmacokinetic blood collections should be performed in said order.
2 A brief physical examination will include, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen (liver an d spleen).
[ADDRESS_326870] dose of each treatment period.
Table 3 Safety  and PK A ssessments -Part 1, Period 1(Adult Participants )
Procedure1Treatment Period 1
Time point (hours)
Predose 0 0.5 1 1.5 2 2.5 3 4 6 8 12 24 36 48
12-lead ECG2 X X X X X X X X X X X X X X
ECG Holter monitoring X X
Vital signs X X X X X X X X X
Study intervention X
Blood PK sample X X X X X X X X X X X X X X
Urine PK collection3 X X X X X X X X X X
ECG = ele ctrocardiogram; PK = pharmacokinetic.
1 When coinciding with safety and/or PKassessments, ECGs , vital signs, and PK blood collections should be performed in said order.
2 Triplicate 12 -lead ECGs will be measured atpredose. Single 12 -lead ECGs will be mea sured at all other time points.
3 Urine collection intervals include 0 (predose), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours. 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
15Table 4 Safety  and PK A ssessments -Part 1, Period 2 (12-Hour Dose Interval , Adult Participants )
Procedure1Treatment Period 2
Time point (hours)
Predose 0 0.5 1 1.5 2 2.5 3 4 6 8 12 12.5 13 13.5 14 14.5 15 16 18 20 24 36 48 60
12-lead ECG2 X X X X X X X X X X X X X X X X X X X X X X X X
ECG Holter 
monitoringX X
Vital signs X X X X X X X X X X X X X
Study 
interventionX X
Blood PK 
sampleX X X X X X X X X X X X X X X X X X X X X X X X
Urine PK 
collection3X X X X X X X X X X X X X X X
ECG = electrocardiogram ; PK = pharmacokinetic .
1 When coinciding with safety and/or PKassessments, ECGs , vital signs, and PK blood collections should be performed in said order.
2 Triplicate 12 -lead ECGs will be measured at predose. Single 12 -lead ECGs will be measured at all other time points.
3 Urine collection intervals include 0 (predose), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 14 hours, 14 to 16 hours, 16 to 18 hours, 18 to 20 hours, 
20to 24 hours, 24 to 36 ho urs, 36 to 48 hours , and 48 to 60 hours. 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
16Table 5 Safety  and PK A ssessments -Part 1, Period 3 (6-Hour Dose Interval , Adult Participants )
Procedure1Treatment Period 3
Time point (hours)
Predose 0 0.5 1 1.5 2 2.5 3 4 6 6.5 7 7.5 8 8.5 9 10 12 14 18 24 36 48 60
12-lead ECG2 X X X X X X X X X X X X X X X X X X X X X X X
ECG Holter 
monitoringX X
Vital signs X X X X X X X X X X X X X
Study 
interventionX X
Blood PK 
sampleX X X X X X X X X X X X X X X X X X X X X X X
Urine PK 
collection3X X X X X X X X X X X X X X
ECG = electrocardiogram ; PK = pharmacokinetic .
1 When coinciding with safety and/or PKassessments, ECGs , vital signs, and PK blood collections should be performed in said order.
2 Triplicate 12 -lead ECGs will be measured at predose. Single 12 -lead ECGs will be measured at all other time points.
3 Urine collection intervals include 0 (predose), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 10 hours, 10 to 12 hours, 12 to 14 hours, 14 to 18 hours, 18 to 24hours, 
24to 36 hours, 36 to 48 hours , and 48 to 60 hours. 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
17Table 6 Schedule of A ctivities -Part 2 (Adolescent Participants)
Procedure1Check- inTreatment Period 1
(Days)Check-
in2Treatmen t Period 2
(Days)Follow -up 
(7[±3] days 
after last 
dose ) or Early 
TerminationNotes–1 1 2 3 –[ADDRESS_326871] (if 
WOCBP), as appropriate 
(see Table 10)
Drug,alcohol, and cotinine
screenX X See Table 10
Laboratory assessment s X X X X XIncluding serum chemistry, 
hematology, and urinalysis
(see Appendix 2)
12-lead ECG5 X X X X X X X X XSee Table 7,Table 8, and 
Table 9 for timing of 
assessments
ECG Holter monitoring6 X X X X X XSee Table 7, Table 8, and 
Table 9 for timing of 
assessments
Vital signs X X X X X X X X XSee Table 7, Table 8, and 
Table 9 for timing of 
assessments
Study intervention X XSee Table 7, Table 8, and 
Table 9 for tim e points
Blood collection for 
pharmacokineticsX X X X X XSee Table 7, Table 8, and 
Table 9 for tim epoints 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
18Procedure1Check- inTreatment Period 1
(Days)Check-
in2Treatmen t Period 2
(Days)Follow -up 
(7[±3] days 
after last 
dose ) or Early 
TerminationNotes–1 1 2 3 –1 1 2 3
Urine collection for 
pharmacokineticsX X X X X XSee Table 7,Table 8, and 
Table 9 for time points
AE/SAE review X ================================================ =============== X
Concomitant medication 
reviewX ================================================ =============== X
AE = adverse event, ECG = electrocardiogram, SAE = serious AE; WOCB P =wom an of childbearing potential.
1 When coinciding with safety and/or pharmacokinetic assessments, ECGs , vital signs, and pharmacokinetic blood collections should be performed in said order.
2 Check- in procedures only necessary if participant leaves th e clinic between Treatment Period 1 and Treatment Period 2.
3 Participants may be discharged from the clinic after the Hour 48 assessments.
4 A brief physical examination will include, at a minimum, assessments of the skin, lungs, cardiovascular system, an d abdomen (liver and spleen).
5 Triplicate 12 -lead ECGs will be measured on Day -1 (before each treatment perio d).
[ADDRESS_326872] dose of each treatment period. 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
19Table 7 Safety  and PK A ssessments -Part 2, Period 1 (Adolescent Participants )
Procedure1Treatment Period 1
Time point (hours)
Predose 0 0.5 1 1.5 2 2.5 3 4 6 8 12 24 36 48
12-lead ECG2 X X X X X X X X X X X X X X
ECG Holter mon itoring X X
Vital signs X X X X X X X X X
Study intervention X
Blood PK sample X X X X X X X X X X X X X X
Urine PK collection3 X X X X X X X X X X
ECG = electrocardiogram; PK = pharmacokinetic .
1 When coinciding with safety and /or PKassessments, ECGs , vital signs, and PK blood collections should be performed in said order.
2 Triplicate 12 -lead ECGs will be measured at predose. Single 12 -lead ECGs will be measured at all other time points.
3 Urine collection intervals include 0 (predose), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours.
Note: The number of PK samples and the PK sampling time points may be modified based on the adult PK data from Part 1. 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
20Table 8 Safety  and PK A ssessments -Part 2, Period 2 (if6-hour dose interval is selected , Adolescent Participants )
Procedure1Treatment Period 2
Time point (hours)
Predose 0 0.5 1 1.5 2 2.5 3 4 6 6.5 7 7.5 8 8.5 9 10 12 14 18 24 36 48
12-lead ECG2 X X X X X X X X X X X X X X X X X X X X X X
ECG Holter 
monitoringX X
Vital signs X X X X X X X X X X X X
Study 
interventionX X
Blood PK 
sampleX X X X X X X X X X X X X X X X X X X X X X
Urine P K 
collection3X X X X X X X X X X X X X
ECG = electrocardiogram ; PK = pharmacokinetic .
1 When coinciding with safety and/or PKassessments, ECGs , vital signs, and PK blood collections should be performed in said order.
2 Triplicate 12 -lead ECGs will be me asured at predose. Single 12 -lead ECGs will be measured at all other time points.
3 Urine collection intervals include 0 (predose), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 10 hours, 10 to 12 hours, 12 to 14 hours, 14 to 18 hours, 18 to 24hours, 
24to 36 hours, and 36 to 48 hours.
Note: The number of PK samples and the PK sampling time points may be modified based on the adult PK data from Part 1. 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
21Table 9 Safety  and PK A ssessments -Part 2, Period 2 ( if12-hour dose interval is selected , Adolescent Participants )
Procedure1Treatment Period 2
Time point (hours)
Predose 0 0.5 1 1.5 2 2.5 3 4 6 8 12 12.5 13 13.5 14 14.5 15 16 18 20 24 36 48
12-lead ECG2 X X X X X X X X X X X X X X X X X X X X X X X
ECG Holter 
monitoringX X
Vital signs X X X X X X X X X X X X
Study 
interventionX X
Blood PK 
sampleX X X X X X X X X X X X X X X X X X X X X X X
Urine PK 
collection3X X X X X X X X X X X X X X
ECG = electrocardiogram; PK = pharmacokinetic.
1 When coinciding with safety and/or PKassessments, ECGs , vital signs, and PK blood collections should be performed in said order.
2 Triplicate 12 -lead ECGs will be measured at predose. Single 12 -lead ECGs will be measured at all other t ime points.
3 Urine collection intervals include 0 (predose), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 14 hours, 14 to 16 hours, 16 to 18 hours, 18 to 20 hours, 
20to 24 hours, 24 to 36 hours, and 36 to 48 hours.
Note: The number of PK samples and the PK sampling time points may be modified based on the adult PK data from Part 1.
In Part 2, Period 2, t he timing and number of planned study  assessments , including safety, pharmacokinetic ( PK), or other
assessments may  be a ltered during the course of the study  based on data from Part 1 (e.g., to obtain data closer to the time of 
peak plasma concentrations) to ensure appropriate monitoring.
Any changes in the timing or addition of time points for any  planned stud y assessments as the result of emerging PKdata from
Part [ADDRESS_326873] be documented and approved b y the GlaxoSmithKline ([COMPANY_004]) study  team and then archived in the sponsor and site 
study  files, but will not constitute a protocol amendment. The Institutional Review Board (I RB)/Independent Ethics Committee 
(IEC) will be informed of an y safety issues that constitute a substantial amendment and require alteration of the safet y 
monitoring scheme or amendment of the informed consent form (I CF)/assent . The changes will be approved b ythe competent 
authorities ( CA)and the ethics committee ( EC) before implementation. 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
222. INTRODUCTION
Gepotidacin ([COMPANY_004]2140944) is a first in class, novel triazaacenaphth ylene antibacterial
that inhibits bacterial ty pe II topoisomerases. It has activity  versu s key  pathogens,
including drug- resistant strains associated with a range of conventional and biothreat
infections and is being developed with intravenous (IV) and oral formulations.
Gepotidacin has demonstrated in vitro activity  and in vivo efficacy  again st conventional
and biothreat pathogens, including isolates resistant to existing classes of antimicrobials.
Gepotidacin selectively inhibits bacterial DNA gyrase and topoisomerase IV by  a unique
mechanism, which is not utilized by  [CONTACT_268684] h uman therapeutic agent.
Structural data with a t ype II topoisomerase, DNA gy rase, reveals the novel binding
mode of the class and distinguishes it from the binding mode of the quinolone
antibacterials [ Bax, 2010]. As a consequence of i ts novel mode of action, gepotidacin is
active in vitro against target pathogens carry ing resistance determinants to established
antibacterials, including fluoroquinolones.
2.1. Stud y Rationale
Single oral doses of gepotidacin (1500 and 3000 mg) were given to p atients with 
gonorrhea in a completed Phase II stud y, and both doses achieved >95% efficacy ; 
however, in vitro data and pharmacokinetic (PK)/pharmacod ynamic modeling revealed 
that a higher dose would prevent the development of resistance and cover organism s with 
higher minimum inhibitory  concentration (MIC).
The selected total daily  dose for gonorrhea is 6000 mg delivered as two 3000 mg doses 
given either 6 or 12 hours apart in order to keep Cmax under a threshold of 14 µg/mL  to 
mitigate the occurrence of a dverse events (AEs) due to acet ylcholinesterase (AChE) 
inhibition (mild and transient AEs of increased salivation, blurred vision, and slurred 
speech were observed following high IV doses as a 1 or 2 hour infusion during a previous 
study ).
Although total d aily oral [ADDRESS_326874] been given to healthy participants and 
patients as 2000 mg three times daily  (TID) for up to 14 day s and daily  IV 4500 mg 
(equivalent to 9180 mg oral dose and based on absolute bioavailability  of 46%) doses 
have been given to h ealthy  participants as TID regimen for up to [ADDRESS_326875] not been characterized 
previously  and gepotidacin has not been administered previousl y to adolescents. 
Therefore, this study  will support inclusion of adolescents with a bod y weight ≥40 kg in 
future Phase III studies and will provide the safet y and PK data of two 3000 mg doses 
separated b y the selected dose intervals in Part 1 and Part 2.
2.2. Background
Gepotidacin has demonstrated clinical efficacy in a Phase II study  for acute bacterial skin 
and skin structure infections, and in a Phase II study  for gonorrhea. 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
23A detailed description of the chemistry , pharmacology , efficacy , and safet y of 
gepotidacin is provided in the I nvestigator’ s Brochure [GlaxoSmithKline Document 
Number CM20 10/[ZIP_CODE]/ 06].
2.3. Benefit/Risk A sses sment
Summaries of findings from both clinical and nonclinical studies conducted with 
gepotidacin can be found in the I nvestigator’s Brochure. The following section outlines 
the risk assessment and mitigation strategy  for this protocol. 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
242.3.1. Risk A ssessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) Gepotidacin
Gastrointestinal (GI) Effects
Based on nonclinical data, gastrointestinal effects were 
mild ulceration of the nonglandular mucosa and minimal 
erosion and/or mural inflammation of the glandular mucosa 
in stomach (rat, oral study); moderate cecal ulceration and 
minimal colonic erosion (rat, IV study); and vomiting (dog).
Lower gastrointestinal effects (soft stools, flatulence, and 
diarrhea) are among the most common AEs reported in 
gepotidacin clinical studies.Gastrointestinal effects observed in gepotidacin clinical 
studies, both Phase I studies and the Phase II ABSSSI 
study, included diarrhea (very common, ≥10% ) and 
flatulence (common; ≥1%  and <10%); all nonserious and 
mild in severity (see Section 6 of the I nvestigator’s 
Brochure).
In the Phase II urogenital gonorrhea study, the most 
frequently reported gastrointestinal AEs overall were 
diarrhea, flatulence, abdominal pain, and nausea. 
Comparing the treatment groups, the incidence of diarrhea 
and nausea was higher in the [ADDRESS_326876] been 
reported in clinical studies (see Section 6 of the IB). Of the 
282healthy participants in Phase I studies who have 
received gepotidacin, C.difficile was reported in 
8particip ants, including 2 elderly participants in 
association with soft stools or diarrhea. In the Phase I renal 
impairment and hepatic impairment studies and in the 
Phase II ABSSSI, urogenital gonorrhea, and uUTI studies, 
no cases of C.difficile -associated diarr hea were reported.Exclusion criterion and close monitoring of clinical 
parameters and AEs will be conducted to mitigate and 
assess GI effects.
Suspected C. difficile infection will be managed according 
to a prespecified algorithm provided in Appendix 7.
Participant evaluation criteria: Participants experiencing 
Grade 3 or Grade 4 AEs will be followed as appropriate 
until resolution of the AE (see Section 7.1.3 ). 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
25Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Cardiovascular Effects
Reve rsible increase in QT prolongation and a mild 
increase in heart rate in human participants.In Study BTZ115775 (see [COMPANY_004] Document Number 
2015N227098_00 Study ID BTZ115775 ), the infusion of 
gepotidacin at a dose of [ADDRESS_326877] of approximately 
6bpm to 10 bpm and a QT prolongation, measured as 
∆∆QTcF, of [ADDRESS_326878] been 
seen in the clinic (Phase I studies, including renal 
impairment and hepatic impairment studies, and Phase II 
ABSSSI and uUTI [acute cystitis] studies) (see Section 6 in 
the IB). There were electrocardiographic changes noted in 
a Phase I hepatic impairment study. The majority of 
participants with severe hepatic impairment had both 
predose and maximum postdose ECG paramet er QTcB 
and QTcF values of <450 to ≤[ADDRESS_326879] segment 
elevation and palpi[INVESTIGATOR_814] (1 participant each) in the 
1500- mg treatment group and tachycardia (1participant) in 
the 3000 -mg treatment group.Exclusion criteria, close monitoring of clinical parameters, 
and AEs will be conducted and stoppi[INVESTIGATOR_249193].
Note: Participants with ba seline Q TcF interval >450 msec 
will be excluded.
Participant monitoring criteria: Participants experiencing a 
QTcB and/or QTcF >500 msec and/or a change from 
baseline in QTc >60 msec (see Section 7.1.2 ).
Acetylcholinesterase (AChE) Inh ibition
In a mass spectrometry model performed with gepotidacin, 
AChE was inhibited with a concentration of inhibitor where 
the response (or binding) was reduced by [CONTACT_2016] (inhibitory 
concentration) of approximately 5 µg/mL (7.5 µg/mL of 
total drug concentra tion).At higher doses, some participants have experienced 
effects consistent with increased cholinergic tone, including 
central nervous system and GI effects ( increased 
salivation, slurred speech, blurred vision, dizziness, 
light-headedness, and GI upset) . These effects appear to 
be related to Cmax and are significantly attenuated when 
Cmax is below 14 g/mL.Coadministration of anticholinergics and administration in 
participants with certain concomitant conditions will be 
excluded.
Close monitoring of clinical parameters and AEs will be 
conducted to assess effects potentially related to AChE 
inhibition. The Cmax is expected to be below 14 g/mL in 
this study. 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
26Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Rash/Hypersensitivity A fine, mild, generalized pruritic macular skin rash was 
seen in 3 of 6participants following 10 days of dosing 
1500 mg 3 times daily (see [COMPANY_004] Document Number 
2014N198291_00 Study ID BTZ115198).
Rash was reported as an AE for 4 of 122 participants (3%) 
and consisted of mild, relat ed urticaria; moderate, related 
rash maculopapular; mild, related rash; mild, related 
urticaria; and mild, not related arthropod bite (see [COMPANY_004] 
Document Number 2015N243789_00 Study ID 
BTZ116704).
There has been no other evidence of hypersensitivity in 
human participants to date.Exclusion criterion :
History of sensitivity to any of the study drugs, components 
thereof, or a history of drug or other allergy that, in the 
opi[INVESTIGATOR_268661], contraindicates their participation.
Participant monitoring:
Participants will be monitored closely for cutaneous effects 
throughout the study, and specialist advice will be sought 
as needed to evaluate any clinically significant find ing.
Participant evaluation criteria :
Grade 3 or higher rash or Grade 2 rash with evidence of 
systemic involvement (see Section 7.1.4 ).
bpm=beats per minute; ABSSSI =acute bacterial skin and skin structure infection; AE =adverse event; Cmax =maximum concentration; ECG =electrocardiogram; IB = Investigator’s 
Brochure; IV =intravenous; ΔΔQTcF =placebo -corrected change -from-baseline in corrected QT interval using the Fridericia formula; QTc =corrected QT interval; QTcB =QT interval 
corrected for heart rate according to Bazett; QTcF =interval corrected for heart rate accor ding to Fridericia; uUTI =uncomplicated urinary tract infection. 
 
 2019N422403_00
2019N401 436_00 CONFIDENTIA L
[ADDRESS_326880] clinical benefit to study  participants. Participation in this study will 
contribute to the process of developi[INVESTIGATOR_268662].
2.3.3. Overall Benefit: Risk Conclusion
The risk of AEs is minimized for the populations being investigated in the proposed study  
by [CONTACT_268685] o f dose and participants for the study , the relativel y short duration of 
study  drug exposure, and the extent of safet y monitoring incorporated into the study.
3. OBJECTIVES A ND ENDPO INTS
Objectives Endpoints
Primary
Part 1
To evaluate the pharmacokinetics of a 
single 1500 -mg dose and two 3000 -mg 
doses of gepotidacin given 6 and 
12hours apart in adult participants1500 mg Single Dose
 Plasma gepotidacin AUC(0-t), AUC(0-∞ ), 
AUC(0 -24), AUC(0 -48), and Cmax, as data 
permit
3000 mg Two Doses
 Plasma gepotidacin AUC(0-t), AUC(0- τ), 
AUC(0 -24), AUC(0 -48), Ro (accumulation 
ratio), and Cmax, as data permit
Part 2
To evaluate the pharmacokinetics of a 
single 1500 -mg dose andtwo 3000-mg 
dose sof gepotidacin given at a dosing 
interval (to be determined) in 
adolescent participants1500 mg Single Dose
 Plasma gepotidacin AUC(0 -t), AUC(0- ∞), 
AUC(0 -24), AUC(0 -48), and Cmax, as data 
permit
3000 mg Two Doses
 Plasma gepotidacin AUC(0- t), AU C(0-τ), 
AUC(0 -24), AUC(0 -48), Ro (accumulation 
ratio), and Cmax, as data permit
Parts 1 and 2
To assess the safety of gepotidacin in 
adult participants and adolescent 
participantsAdverse events, clinical laboratory tests, 
vital signs (systolic and diastolic blood 
pressure and heart rate) , and 12 -lead 
electrocardiogram readings 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
28Objectives Endpoints
Secondary
Part 1
To assess the urine pharmacokinetics
of gepotidacin following a single 
1500 -mg dose andtwo 3000 -mg doses 
of gepotidacin given 6 and 12 hours 
apart in adult p articipants Urine endpoints include A etotal, Ae(t1 -t2), 
AUC(0 -τ), AUC(0 -24), AUC(0 -48), fe%, 
and CLr of gepotidacin, as data permit
Part 2
To assess the urine pharmacokinetics
of gepotidacin following a single 
1500 -mg dose andtwo 3000 -mg doses 
of gepotidacin given at a dosing interval 
(to be determ ined) in adolescent 
participants Urine endpoints include A etotal, Ae(t1 -t2), 
AUC(0 -τ), AUC(0 -24), AUC(0 -48), fe%, 
and CLr of gepotidacin, as data permit
Parts 1 and 2
To assess the plasma 
pharmacokinetics of gepotidacin Plasma gepotidacin Tmax, tlag, a nd t1/2, 
as data permit
4. STUDY DESIGN
4.1. Overall Design
This is a Phase I, double -blind, single- center, randomized, sequential, two -part study . 
Part 1 is being conducted to evaluate the PK of the gepotidacin tablets in healthy  adult 
participants. Part 2 will evaluate the PK of the gepotidacin tablets in healthy  adolescent 
participants.
Part 1: Pharmacokinetics in Healthy Adult Participants
Part 1 is a 3 -period, fixed -sequence stud y that will assess the PK of a single 1500 -mg 
dose (Period 1) and two 3000 -mg do ses of gepotidacin at Hours 0 and 12 (Period 2) and 
Hours 0 and 6 (Period 3) in healthy  adult participants. 
Participants will be randomly  assigned to receive either all active treatment (gepotidacin) 
or placebo for all 3 periods. Approximately  17 particip ants will be randomized (in a 
14:3 ratio) to receive a single dose of gepotidacin 1500 mg (Treatment A) or matching 
placebo (Treatment B) in Period 1 ,gepotidacin 3000 mg separated b y 12 hours 
(Treatment C) or matching placebo (Treatment D) in Period 2, and gepotidacin 3000 mg 
separated b y 6hours (Treatment E) or matching placebo (Treatment F) in Period 3 to 
obtain 12 evaluable participants on active treatment and 2 evaluable participants on 
placebo. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
29Participants will participate in 3treatment periods, and blood and urine samples will be 
collected for PK anal ysis of gepotidacin concentrations according to the Schedule of 
Activities ( SoA; see Section 1.3).
This will be a two- part study  in which the PK andsafet y data will be rev iewed after 
completion of Part 1 before enrolling participants into Part 2. The dosing interval in 
Part2, Period 2 will be based on the PK, safet y, and tolerability data from Part 1.
Part 2: Pharmacokinetics in Healthy Adolescent Participants
Part 2 is a 2-period, fixed sequence study  that will assess the PK of a single 1500 -mg 
dose (Period 1) of gepotidacin and two 3000 -mg doses (Period 2) of gepotidacin in 
healthy  adolescent participants. The two 3000 -mg doses will be separated by  a time 
interval that will be determined based on data from Part 1. The number of PK samples 
and the PK sampling time points may  be modified based on the adult PK data from 
Part1.
Participants will be randomly  assigned to receive either all active treatment (gepotidacin) 
or plac ebo for both periods. Approximately  17 participants will be randomized (in a 
14:3 ratio) to receive a single dose of gepotidacin 1500 mg (Treatment A) or matching 
placebo (Treatment B) in Period 1 and gepotidacin 3000 mg (Treatment G) or matching 
placebo ( Treatment H) in Period 2 to obtain 12 evaluable participants on active treatment 
and 2 evaluable participants on placebo.
The interval for the two 3000- mg doses in Period 2 will be between 6 hours and 12 hours 
based on the PK and safety  results from Part 1 .
Participants will participate in 2 treatment periods , and blood and urine samples will be 
collected for PK anal ysis of gepotidacin concentrations according to the SoA 
(seeSection 1.3).
For Part [ADDRESS_326881] been given to healthy  participants and 
patients as 2000 mg TID for up to 14 day s and daily  IV 4500 mg ( equivalent to 9180 mg 
oral dose and based on absolute bioavailability  of 46%) doses have been given to health y 
participant s as TID regime n for up to [ADDRESS_326882] not been characterized previously  and gepotidacin 
has not been administered previously  to adolescents; this study  will support inclusion of 
adolescents with a body weight ≥40 kg in future Phase IIIstudiesand will provide the 
safet y and PK data of two 3000 mg doses separated by [CONTACT_268686]1 and Part 2. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
30Both adult and adolescent (≥ 12 to <18 y ears of age) eligible participants will be enroll ed 
in this double -blinded study .Adolescent participants will only  be enrolled if allowed per 
the study  site’s IRBand national regulatory  guidelines, and enrollment will be contingent 
upon such approvals. Adolescent assent forms and adult consent forms will be developed 
with oversight from local governing IRB (see Appendix 3).
Part 1 is being conducted to evaluate the pharmacokinetics, safet y, and tolerability of the 
gepotidacin tablet .
Part 2 will evaluate the pharmacokinetics, safety, and tolerability of the gepotidacin tablet
in adolescent participants. Testing gepotidacin in this specific population will provide 
PK, safet y, and tolerability information needed for their inclusion in future pi[INVESTIGATOR_268663] .
4.3. Justification fo r Dose
Selection of dose and dosing frequency  for this study  is justified based on observed safet y 
efficacy  and PK data following single oral dosing (1500 to 3000 mg), repeat oral twice 
daily  (BID; 1500 to 2300 mg) and TID dosing (1500 to 2000 mg) in previ ous studies. In 
addition ,exposures higher than anticipated in this study  were achieved following single 
IV dosing of 1800 mg equivalent to an oral dose of 3913mg (absolute bioavailability  is 
46%) and repeat IV dosing of 1500 mg TID for 10 days (equivalen t to an oral daily  dose 
of approximately  9180 mg).
Based on PK modeling, gepotidacin will be administered for gonorrhea as twosingle oral 
3000 -mg doses, given either 6 or 12 hours apart with a minimum body  weight of 40 kg, 
to provide higher dail y systemic exposures that allow coverage of Neisseria gonorrhoeae
isolates with higher gepotidacin MI C values, which are likel y to be observed in the global 
Phase IIIstudy  and reduce the risk of resistance emergence. Less than 3% of the 
population isexpected to e xceed the Cmax threshold of 14 µg/mL .
In the current study , gepotidacin will be administered as a single oral [ADDRESS_326883] completed the study  if he/she has completed all 
phases of the stud y including the final date on which data were or are expected to be 
collected.
The end of the stud y is defined as the date of the last visit of the last participant in the 
study  or last scheduled visit shown in the SoA ( see Section 1.3) for the last participant in 
the study . 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
315. STUDY POPULA TION
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not p ermitted.
If participants prematurely discontinue the stud y, additional replacement participants may 
be recruited at the discretion of the s ponsor in consultation with the investigator.
Replacement participants will be assigned to the same randomization se quence as the 
participant who discontinued.
5.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria 
apply :
Age
1.Participant in Part [ADDRESS_326884] be ≥18 to ≤64years of age inclusive, at the time of signing 
the informed consent.
2. Participant in Part [ADDRESS_326885] be ≥ 12 to <18years of age inclusive, at the time of signing 
the informed consent/assent .
Type of Participant and Disease Characteristics
3.Participants who are healthy  as determined b y the investigator or medic ally qualified 
designee based on medical evaluation including medical history , phy sical 
examination, clinical laboratory  tests, vital sign measurements, and 12- lead 
electrocardiogram (ECG) results <450 millisecond ( msec ). A participant with 
clinical abnorm ality or laboratory parameters outside the reference range for the 
population being studied may  be included onl y if the investigator feels and 
documents that the finding is unlikely  to introduce additional risk factors and will not 
interfere with the study procedures.
Weight
4.Body weight ≥40 kg and body  mass index (BMI ) within the range 18.5 – 32.0 kg/m2
(inclusive).
Sex
5.Male and/or female
a. Female Participants:
A female participant is eligible to participate if she is not pregnant or breastfeeding, 
and at lea st one of the following conditions applies:
oIs not a woman of childbearing potential (WOCBP) 
OR 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
32oIs a WOCBP and using a contraceptive method that is highly  effective, with a 
failure rate of <1%, as described in Appendix 5for at least [ADDRESS_326886] dose of study  intervention.
A WOCBP must have a highl y sensitive negative pregnanc y test before the first dose 
of study  intervention.
Informed Consent
6. C apable of giving signed informed consent /assent as described in Appendix 3which 
includes compliance with the requirements and restrictions listed in the I CF/assent
and in this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions
1.Clinically  significant abnormality  in the past medical history  or at the Screening 
physical examination that in th e investigator’s opi[INVESTIGATOR_268664]. This includes, but is not limited 
to, history  or current cardiac, hepatic, renal, neurologic, gastrointestinal (GI), 
respi[INVESTIGATOR_696] , hematologic, or i mmunologic disease.
2.Any surgical or medical condition (active or chronic) that may  interfere with drug 
absorption, distribution, metabolism, or excretion of the study  intervention, or any  
other condition that may place the participant at risk, in the opi[INVESTIGATOR_268665].
3.Female participant has a positive pregnancy  test result or is lactating at Screening or 
upon admission to the clinic.
4.Use of an y systemic antibiotic within [ADDRESS_326887].
6.Current or chronic history of liver disease or known hepatic or biliary  abnormalities 
(with the exception of Gilbert’s sy ndrome or as ymptomatic gallstones).
7. H istory  of drug and/or alcohol abuse within 6 months before Screening, as 
determined b y the investigator, or has a positive drug screen at Screening or upon 
admission to the clinic.
8.History  of sensitivity  to any  of the stud y drug, components thereof, or a h istory  of 
drug or other allergy  that, in the opi[INVESTIGATOR_268666].
9.History  of sensitivity  to heparin or heparin -induced thrombocy topenia (if the clinic 
uses heparin to maintain intravenous c annula patency ). 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
33Prior/Concomitant Therapy
10.Participants must abstain from taking prescription or nonprescription drugs (except 
for hormonal contraceptives and/or acetaminophen), vitamins, and dietary  or herbal 
supplements, unless specifi edin Section 6.5, within 7 days (or 14 day s if the drug is 
a potential enzy me inducer) or 5 half -lives (whichever is longer) prior to study  
intervention until completion of the Follow- up Visit, unless, in the opi[INVESTIGATOR_268667], the medication will not interfere with the study . Any  
exceptions will be discussed with the sponsor or medical monitor on a case -by-case 
basis and the reasons will be documented.
Prior/Concurrent Clinical Study Experience
11.Previous exposure to gepotidacin within [ADDRESS_326888] (whichever is longer).
Diagnostic assessments
13. P resence of hepatitis B surface antigen or positive hepatitis C antibody  test result at 
Screening or within 3 months prior to starting study  intervention.
14.Alanine aminotransfer ase (ALT) >1.5 × upper limit of normal (ULN) .
15.Bilirubin >1.5 × ULN (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is 
fractionated and direct bilirubin <35%).
16.History  of any  kidney  disease or current or chronic history  of impaired renal function 
as indicated b y an estimated creatinine clearance <60 mL /min.
17.A positive test for human immunodeficiency  virus antibody .
18.History  of regular alcohol consumption within 6 months of screening defined as an 
average weekl y intake of >21 units (or an average daily  intake of >3 units) for males 
or an average weekly  intake of >14 units (or an average daily  intake >2 units) for 
females. One unit is equivalent to 270 mL  of full strength beer, 470 mL of light beer, 
30 mL  of spi[INVESTIGATOR_2120], or 100 mL  of wine.
19.Urinary  cotinine level indicative of smoking or history  or regular use of tobacco- or 
nicotine -containing products within 3 months before Screening.
20. C linically  significant abnormal findings in serum chemistry , hematology , or 
urinaly sis results obtained at Screening or Day -1. 
21. B aseline corrected QT interval using the Fridericia formula (QTcF) of >[ADDRESS_326889] yleConsiderations
5.3.1. Meals and Dietary  Restrictions
All doses of study  intervention (gepotidacin or placebo) should be after food 
consumption (a standard meal) and with approximately  240 mL of water. Up to 
480mL of water is allowed if the participant has difficulty  swallowing multiple 
tablets.
Prior to the morning dose, participants will fast (no food or drink except water) for 
approximately  [ADDRESS_326890] meals will be provided during the stud y treatment period at times that do 
not interfere with study  procedures.
For doses scheduled to occur [ADDRESS_326891] meal 
(similar in calorie content and similar ratio s of protein, carboh ydrates, and fat as the 
previous meal ) prior to the second dose. Participants should consume this meal in 
30 minutes or less. Dose administration will occur within 5 minutes of completion of 
meal consumption. Participants will not recei ve any  further food until 2 hours after 
dosing.
Refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit 
juice, pomelos, exotic citrus fruits, grapefruit hy brids, or fruit juices from 7 day s 
before the start of dosing until after col lection of the final PK sample.
No water is allowed until 2 hours after dosing, unless administered under the 
investigator’s direct order for treatment of an AE. W ater is allowed ad libitum at all 
other times.
Standard meals will be provided during the stu dy dosing period at specified times.
5.3.2. Caffeine, Alcohol , and Tobacco
Participants will abstain from ingesting caffeine -or xanthine -containing products 
(e.g., coffee, tea, cola drinks, and chocolate) for24hours before the start of dosing 
until after colle ction of the final PK sample.
Participants will abstain from alcohol for 24 hours before the start of dosing until 
after collection of the final PK sample. 
Use of tobacco products will not be allowed from 3 months before Screening until 
after the final Follow-up visit. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
355.3.3. Activity
Participants will abstain from strenuous exercise for 48 hours before each blood
collection for clinical laboratory  tests. Participants may  participate in light 
recreational activities during the study (e.g., watching television, re ading).
5.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  
but are not subsequentl y enrolled in the study . A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to 
meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regulatory  authorities. Minimal information 
includes demograph y, screen failure details, eligibility  criteri a, any protocol deviations, 
and an y serious adverse events (SAE s).
Individuals who do not meet the criteria for participation in this study  (screen failure) 
may be rescreened. Participants should be assigned a new participant number for every  
screening/re -screening event.
6. STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, or medical device (s)intended to be administered to a study  participant according 
to the study  protocol. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
366.1. Stud y Intervent ions A dministered
Intervention Name [CONTACT_268691] s, 750 mg Placebo (Matched to 
Gepotidacin Tablets )
Type Tablets containing gepotidacin 
mesylate ([COMPANY_004]2140944E ) and 
inactive formulation excipi[INVESTIGATOR_268668]- dose gepotidacin 
placebo -to-match tablet
Dose Fo rmulation Tablet Tablet
Unit Dose Strength(s) 750 mg Not applicable
Dosage Level(s) Part 1 , Period 1 :
2 x 750 mg single dose
Each dose should be taken 
after food consumption and 
with water
Part 1 , Periods 2 and 3 :
[ADDRESS_326892] 
dose (6000 mg total daily dose)
Each dose should be taken 
after food consumption and 
with water
Part 2, Period 1:
2 x 750 mg single dose
Each dose should be taken 
after food consumption and 
with water
Part 2 , Period 2 :
4 x 750 mg two do ses given at 
an interval to be determined 
after review of safety and PK 
data from Part 1 (6000 mg total 
daily dose)
Each dose should be taken 
after food consumption and 
with waterPart 1 , Period 1 :
Administer 2tablets as a single 
dose
Each dose should be taken 
after food consumption and 
with water
Part 1, Periods 2 and 3:
Administer 4 tablets (two 
doses) ; second dose given
either [ADDRESS_326893] 
dose
Each dose should be taken 
after food consumption and 
with water
Part 2, Period 1:
Administer 2 tablets as a single 
dose
Each dose should be taken 
after food consumption and 
with water
Part 2 , Period 2 :
Administer 4 tablets (two 
doses) given at an interval to 
be determined after review of 
safety and PK data from Part 1
Each dose should be taken 
after food consumption and 
with water 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
37Route of Administration Oral Oral
IMP and NIMP IMP IMP
Sourcing Provided centrally by [CONTACT_268687]-density polyethylene 
(HDPE )bottles. Each bottle will 
be labeled as required per 
country requirement.Placebo will be provided in 
HDPE bottles. Each bottle will 
be labeled as required per 
country requirement.
6.2. Preparation/Handling/Storage/A ccountability
1.The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention received and any  
discrepancies are reported and resolved before use of the study  intervention.
2.Only  participants enrolled in the study  may  receiv e study  intervention ,and only  
authorized site staff may  supply  or administer study  intervention. All study  
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated) area in accordance with the labeled storag e conditions with 
access limited to the investigator and authorized site staff.
3.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
mainte nance ( i.e., receipt, reconciliation, and final disposition records).
4.Further guidance and information for the final disposition of unused study  
intervention are provided in the Study  Reference Manual (SRM) .
Under normal conditions of handling and administration, study  intervention is not 
expected to pose significant safety risks to site staff .
A Material Safety  Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investig ator, where this is required b y local laws, or is available upon request from 
[COMPANY_004].
6.3. Measures to Minimize Bias: Randomization and Blinding
This is a double -blind study . The stud y treatment taken during the stud y will be 
double -blind. An unblinded pharmacist will dispense study  intervention . Neither the 
participant nor immediate study  personnel (i.e., investigators, [COMPANY_003] staff) will know which 
study  treatment the participant is receiving. Participants who are randoml y assigned to 
receive placebo will receive a matching placebo form of the active treatment. The 
matc hing placebo s will look identical to the active form. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
38In case of an emergency, the investigator has the sole responsibility  for determining if 
unblinding of a participant’s treatment assignment is warr anted. Participant safet y must 
alway s be the first consideration in making such a determination. If the investigator 
decides that unblinding is warranted, the investigator should make every  effort to contact 
[CONTACT_31820] a participant’s treatmen t assignment unless this could delay  
emergency  treatment of the participant. If a participant’s treatment assignment is 
unblinded ,[COMPANY_004] must be notified within [ADDRESS_326894] be recorded in the source documentation and 
electronic case report form ( eCRF), as applicable.
In Part 1 and Part 2, participants will be randomized in a 14:3 ratio to receive study  
intervention. Investigators will remain blinded to each participant’s assigned study
intervention throughout the course of the stud y.
Unblinded monitors and in the event of a quality  assurance audit, the auditor will be 
allowed access to unblinded study  intervention records at the site to verify  that
randomization/dispensing has been done accurately .
A participant will be withdrawn if the participant’s intervention code is unblinded by  [CONTACT_1275]. The primary reason for discontinuation (the event or condition which led to 
the unblinding) will be recorded in the eCRF.
To protect the safet y of participants, [COMPANY_004] safety  medical monitor may remain unblinded 
to participant treatment throughout the stud y and willmonitor safety  data in real time. 
Limited members of [COMPANY_004] staff (e.g., statistician, pharmacokineticist , and medical 
monitor ) will be unblinded to study  treatment at the end of Part [ADDRESS_326895] to Part 2.
[COMPANY_004]’s Global Clinical Safet y and Pharmacovigilance (GCSP) staff may  unblind the 
intervention assignment for any  participant w ith an SAE. If the SAE requires that an 
expedited regulatory  report be sent to one or more regulatory  agencies, a copy  of the 
report, identify ing the participant’s intervention assignment, may  be sent to investigators 
in accordance with local regulations and/or [COMPANY_004] policy .
6.4. Stud y Intervention Compliance
When the individual dose for a participant is prepared from a bulk supply , the 
preparation of the dose will be confirmed b y a second member of the stud y site staff. 
When participants are dosed at the site, they  will receive study  intervention directly  
from the investigator or designee, under medical supervision. The date and time of 
each dose administered in the clinic will be recorded in the source documents. The 
dose of study  intervention and study  participant identification will be confirmed at 
the time of dosing b y a member of the stud y site staff other than the person 
administering the stud y intervention . Study  site personnel will examine each 
participant’s mouth to ensure that the study  intervention was inges ted. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
396.5. Concomitant Therapy
Any medication or vaccine (including over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements) that the participant is receiving at the time of 
enrollment or receives during the study must be recorded along w ith:
reason for use
dates of administration including start and end dates
dosage information including dose and frequency
The medical m onitor should be contact[CONTACT_43205] y questions regarding 
concomitant or prior therapy .
Participants must abstain f rom taking prescription or nonprescription drugs (including 
vitamins and dietary  or herbal supplements) within 7 day s (or 14 day s if the drug is a 
potential enzy me inducer) or 5 half -lives (whichever is longer) before the start of study  
intervention until completion of the Follow -up Visit, unless, in the opi[INVESTIGATOR_268667], the medication will not interfere with the study . 
Hormonal contraceptives and/or a cetaminophen, at doses of 2grams/day , are permitted 
for use an y time during the study . Other concomitant medication may  be considered on a 
case-by-case basis b y the investigator in consultation with the m edical monitor.
6.6. Dose Modification
The interval for the two 3000-mg doses in Part 2, Period 2 will be between 6hours and 
12 hours ba sed on the PK and safety  results from Part 1.
6.7. Intervention after the End of the Study
Participants will not receive an y additional treatment from [COMPANY_004] (gepotidacin or placebo )
after completion of the study  because only  healthy participants are eligible for study  
participation.
7. DISCONTINUA TION OF STUDY INTERVENTION A ND 
PARTICIPA NT DISCONTI NUA TION/WITHDRA WAL
7.1. Discontinuation of Study  Intervention
In rare instances, it may  be necessary  for a participant to permanentl y discontinue study  
intervention. If stud y intervention is permanentl y discontinued, the participant will
remain in the study  to be evaluated for safety . See the S oA (see Section 1.3) for data to be 
collected at the time of discontinuation of study  intervention. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
407.1.1. Liver Chem istry Stoppi[INVESTIGATOR_268669] a participant if liver chemistry  stoppi[INVESTIGATOR_118048]:
Phase I Liver Chemistry Stoppi[INVESTIGATOR_2121] –Liver Stoppi[INVESTIGATOR_268670]: ALT = alanine transaminase; INR = int ernational normalized ratio; SAE = serious adverse 
event; ULN = upper limit of normal.
Refer to Appendix 6for required Liver Safet y Actions and Follow -up Assessments .
7.1.2. QTc Stoppi[INVESTIGATOR_2121]
A participant who meets the following bulle ted criteria based on triplicate ECG readings 
will be withdrawn from study  treatment:
Corrected QT ( QTc)>500 msec 
Change from baseline of QTc >60 msec
For p articipants with underly ing bundle -branch block, follow the discontinuation criteria 
listed below:
Baseline QTc with Bundle -Branch Block Discontinuation QTc with Bundle -Branch 
Block
<450 msec >500 msec
450 to 480 msec ≥530 msec
The same QT correction formula must be used for each individual participant to 
determine eligibility  for and discontinuation from the study . This formula may  not be 
changed or substituted once the participant has been enrolled. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
41For example, if a participant is eligible for the protocol based on corrected 
QTcF, then QTcF must be used for discontinuation of this individual participant
as well.
Once the QT correction formula has been chosen for a participant’s eligibility , 
the same formula must continue to be used for that participant for all QTc data 
being collected for data analysis . Safety ECGs and other non -protocol specified 
ECGs are an exception.  
The QTc should be based on single or average dQTc values of ECG readings
obtained over a brief ( e.g., 5 to 10 minute) recording period.  
See the SoA ( see Section 1.3) for data to be collected at the time of intervention
discontinuation and follow- up and for an y further evaluations that need to be completed.
7.1.3. Gastrointesti nal Evaluation Criteria
If a participant meets the criteria i n Appendix 7, C.difficile toxin testing should be 
conducted.
7.1.4. Rash/Hy persensitivity Evaluation Criteria
A participant presenting with a Grade 3 AE or higher rash (diffuse ma cular, 
maculopapular, OR morbilliform rash with vesicles or limited number of bullae; OR 
superficial ulcerations of mucous membrane limited to 1 site) or a Grade 2 rash (diffuse 
macular, maculopapular, or morbilliform rash; OR target lesions) with evidence of 
systemic involvement will be followed as appropriate until resolution of the AE(s).
7.2. Participant Discontinuation /Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request or 
may be withdrawn at any time at the discretion of the investigator for safety , 
behavioral, compliance ,or administrative reasons.
At the time of discontinuing from the stud y, if possible, an earl y discontinuation 
visit should be conducted, as shown in the SoA. See SoA (see Section 1.3)for 
data to be collected at the time of study  discontinuation and follow-up and for 
any further evaluations that need to be completed.
The participant will be permanentl y discontinued both from the study 
intervention and from the study  at that time.
If the participant withdraws consent for disclosure of future information, the 
sponsor may retain and continue to use any  data collected before such a 
withdrawal of consent.
If a participant withdraws from the study , he/she may  request destruction of any  
samples taken and not tested, and the investigator must document this in the site 
study  records. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
[ADDRESS_326896] be taken if a participant fails to return to the clinic for a 
required stud y visit:
The site must attempt to contact [CONTACT_43207]/or should continue in the study .
Before a participant is deemed lost to follow up, the investigator or designee 
must make every  effort to regain contact [CONTACT_6635] (where possible, 
3telephone calls and, if necessary , a certified letter to the participant’s last 
known mailing address or local equivalent methods). These contact [CONTACT_78779]’s medical record.
Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study . 
Discontinuation of specific sites or of the study  as a whole are handled as part of 
Appendix 3.
8. STUDY A SSESSMENTS A ND PROCEDURES
Study  procedures and their timing are summarized in the SoA (see Section 1.3). 
Protocol waivers or exemptions are not allowed .
Immediate safety  concerns should be discussed with the sponsor immediately  
upon occurrence or awareness to determine if the participant should continue or 
discontinue study  intervention .
Adherence to the study design requirements, including those specified in the 
SoA, is essential and required for stud y condu ct.
All screening evaluations must be completed and reviewed to confirm that 
potential participants meet all eligibility  criteria. The investigator will maintain a 
screening log to record details of all participants screened and to confirm 
eligibility  or record reasons for screening failure, as applicable. 
Procedures conducted as part of the participant’s routine clinical management 
(e.g., blood count) and obtained before signing of I CF/assent may be utilized for 
screening or baseline purposes provided the procedure met the 
protocol -specified criteria and was performed within the time frame defined in 
the SoA.
The maximum amount of blood collected from each participant over the 
duration of the study , including any  extra assessments that may  be required, wil l 
not exceed 500mL. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
43Repeat or unscheduled samples may be taken for safet y reasons or for tec hnical 
issues with the samples.
8.1. Efficacy  Assessments
Not applicable.
8.2. Safet y Assessments
Planned time points for all safety  assessments are provided in the SoA (seeSection 1.3).
8.2.1. Physical Examinations
A fullphysical examination will include, at a minimum, assessments of the skin, 
cardiovascular, respi[INVESTIGATOR_696] , gastrointestinal, and neurological s ystems. Height 
and weight will also be measu red and recorded.
A brief ph ysical examination will include, at a minimum, assessme nts of the 
skin, lungs, cardiovascular s ystem, and abdomen (liver and spleen) .
Investigators should pay  special attention to clinical signs related to previous 
serious illne sses.
8.2.2. Vital Signs
Vital signs will be measured in a semi -supi[INVESTIGATOR_55848] [ADDRESS_326897] and 
will include sy stolic and diastolic blood pressure and heart rate. Oral 
temperature andrespi[INVESTIGATOR_268671] .Each 
measurement will be recorded in the eCRF .
8.2.3. Electrocardiograms
Single 12- lead ECG will be obtained as outlined in the SoA (see Section 1.3) 
using an ECG machine that automatically  calculate s the heart rate and measures 
PR, Q RS, QT, and QTc intervals. Refer to Section 7.1.2 for QTc withdrawal 
criteria and additional QTc readings that may  be necessary .
Twelve -lead ECGs will be performed with the participant in a semi- supi[INVESTIGATOR_268672] a rest of at least 10 minutes.
At each time point at which triplicate ECG are required, 3 individual ECG 
tracings should be obtained as closel y as possible in succession but no more than 
2minutes apart. The full set of triplicates should be completed over a brief (e. g., 
5 to 10 minutes) recording period .
ECG Holter monitoring will be obtained as outlined in the SoA
(seeSection 1.3). The Holter monitoring data will be sent to [COMPANY_004] and may  be 
analyzed at a later date. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
448.2.4. Clinica l Safety  Laboratory  Assessments
Refer to Appendix 2forthe list of clinical laboratory  tests to be performed and 
to the SoA ( see Section 1.3) for the timing and frequency . 
The investigator must review th e laboratory report, document this review, and 
record an y clinicall y relevant changes occurring during the stud y in the AE 
section of the eCRF. The laboratory  reports must be filed with the source 
documents. Clinically  significant abnormal laboratory  findings are those that are 
not associated with the underly ing disease, unless judged by  [CONTACT_91006]'s condition.
All laboratory  tests with values considered clinically  significantl y abnormal 
during parti cipation in the study  or until completion of the Follow -up Visit
should be repeated until the values return to normal or baseline or are no longer 
considered significantly  abnormal by  [CONTACT_10982]. 
If such values do not return to no rmal/baseline within a period of time judged 
reasonable b y the investigator, the etiology should be identified and the sponsor 
notified.
All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in acco rdance with the laboratory  manual and the SoA.
8.3. Adverse Ev ents and Serious A dverse Events
The definitions of an AE or SAE can be found in Appendix 4.
The investigator and an y qualified designees are responsible for detecting, document ing, 
and reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AE sthat are serious, considered related to the study  intervention or the 
study , or that caused the participant to discontinue the study (see Section 7). 
8.3.1. Time Period and Frequency  for Collecting A E and SA E 
Information
All SAE swill be collected from the signing of the ICF/assent until the 
Follow -up Visitat the time points specified in the SoA ( see Section 1.3).
All AEs will be collected from the start of intervention until the Follow -up Visit 
at the time points specified in the SoA ( see Section 1.3).
Medical occurrences that begin before the start of study  intervention but after 
obtaining informed consent will be recorded on the Medical History /Current 
Medical Conditions section of e CRF ,not the AE section.
All SAE swill be recorded and reported to the sponsor or designee immediately  
and under no circ umstance should this exceed 24 hours, as indicated in 
Appendix 4. The investigator will submit any  updated SAE data to the sponsor 
within 24 hours of it being available. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
45Investigators are not obligated to activel y seek AEs or SAEs after the conclusion 
of the study  particip ation . However, if the investigator learns of an y SAE, 
including a death, at any time after a participant has been discharged from the 
study , and he/she considers the event to be reasonably  related to the study  
intervention or study  participation, the investigator must promptly  notify  the 
sponsor.
8.3.2. Method of Detecting A Es and SA Es
The method of recording, evaluating, and assessing causality  of AEs and SAEs 
and the procedures for completing and transmitting SAE reports a re provided in 
Appendix 4.
Care will be taken not to introduce bias when detecting AE and/or SAE. 
Open -ended and non -leading verbal questioning of the participant is the 
preferred method to inquire about AE occurrence . 
8.3.3. Follow -up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All SAEs, and nonserious AEs of special interest 
(as defined in Section 2.3.1 ),will be followed until the event is resolved, stabilized, 
otherwise explained, or the participant is lost to follow -up (as defined in Section 7.3). 
Further information on follow -up procedures is given in Appendix 4.
8.3.4. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_11012] a nSAE is essential so 
that legal obligations and ethical responsibilities towards the safet y of 
participants and the safety  of a stu dy intervention under clinical investigation are 
met. 
The sponsor has a legal responsibility  to notify  both the local regulatory  
authority  and other regulatory  agencies about the safet y of a stud y intervention
under clinical investigation. The sponsor wil l comply  with country -specific 
regulatory  requirements relating to safet y reporting to the regulatory authority, 
IRB/IEC, and investigators.
Investigator safety reports must be prepared for suspected unexpected serious 
adverse reactions according to local regulatory  requirements and sponsor policy  
and forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing a nSAE or 
other specific safet y information e.g. , summary  or listing of SAE) from the 
sponsor will review and then file it along with the Investigator’s Brochure and 
will notify  the IRB/IEC, if appropriate according to local requirements. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
468.3.5. Pregnancy
Details of all pregnancies in female participants and, if indicated, female partners of 
male participants will be collected after the start of study  intervention and until 
completion of the Follow -up Visit .
If a pregnancy  is reported, the investigator should inform [COMPANY_004] within 24 hours of
learning of the pregnancy  and should follow the procedures outlined in Appendix 4.
Abnormal pregnancy  outcomes ( e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAE s.
8.4. Treatment of Overdose
Gepotidacin will be administered at the clinic, thus limi ting the risk of overdose. In the 
unlikely  event that an overdose with gepotidacin should occur, the investigator must 
notify  the sponsor promptly . There is no specific antidote for overdose with a bacterial 
topoisomerase inhibitor such as gepotidacin. In the event of a suspected overdose, it is 
recommended that the appropriate supportive clinical care should be instituted, as 
dictated b y the participant’s clinic status.
GlaxoSmithKline does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact [CONTACT_44686] m onitor immediately .
2.Closely  monitor the participant for AE s/SAE sand laboratory  abnormalities until 
gepotidacin can no longer be detected s ystemically  (at least 3 days).
3.Obtain a plasma sample for PK anal ysis within 3days from the date of the last dose 
of study  intervention if requested b y the medical m onitor (determined on a 
case-by-case basis).
4.Document the quantit y of the excess dose as well as the duration of the overdosing in 
the eCRF.
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_268688] m edical monitor based on the clinical evaluation of the 
participant.
8.5. Pharmacokinetics
The PK blood and urine samples will be collected for measuremen t of plasma and 
urine concentrations of gepotidacin at the time points indicated in the 
SoA (seeSection 1.3).The volume of blood required for each PK sample is 
approximately  3mLfor Part 1, and approximately  2 mL for Part 2 .Instructions 
for the collection and handling of biological samples will be provided by  [CONTACT_103]. The actual date and time (24 -hour clock time) of each sample will be 
recorded. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
47Processing, storage, and shippi[INVESTIGATOR_268673]/or laboratory  manual.
Drug concentration information that may  unblind the study  will not be reported to 
investigative sites or blinded personnel until the study  has been unblinded.
8.6. Pharmacody namics
Pharmacod ynamic parameters are no t evaluated in this study .
8.7. Genetics
Genetics are not evaluated in this study .
8.8. Biomarkers
Biomarkers are not evaluated in this study .
8.9. Medical Resource Utilization and Health Economics
Medical Resource Utilization and Health Economics parameters are not eval uated in this 
study .
9. STATISTICA L CONSIDER ATIONS
9.1. Statistical Hy potheses
There is no formal research hy pothesis that will be statistically  tested in this study .
9.2. Sample Size Determination
The PK parameter sample size for this study  was based on feasibility ; however, 
justification has been considered. For the [ADDRESS_326898] 
reference study was BTZ116778, with 1500 mg oral dose (immediate -release capsule) 
taken in fed state, resulting in a coefficient of variation (CV) for AUC(0 -∞) and Cmax of 
21.5% and 40.3% respectively . Precision has been evaluated for a range of plausible 
sample sizes of 10, 12, and 15 participant s exposed to the active dose (see table). The 
precision of sample size of 12 is deemed sufficient for the primary  PK endpoint in this 
study .With 12 participants, the upper limit of the 95% confidence interval for AUC(0 -∞) 
and Cmax will be approximately  14.5% and 28.0% above the geometric means, 
respectivel y.
There were 2studies similar to the 3000 mg BID (at 6 -or 12 -hour intervals) dosing 
regimen. BTZ114595 studied PK profile after a 3000 mg single dose in thefasted s tate, 
with CVfor AUC(0 -∞) and Cmax being 31.5% and 36.0%, respectively . BTZ116576 
studied the 2-hour postdose concentration following a 3000 mg single dose in the fed 
state, with CVfor the concentration being 42.9%. The estimate of AUC(0 -∞) CVwas 
higher after 3000 mg than the 1500 mg dose; however, AUC(0 -∞) appeared less variable 
than Cmax consistently  across doses, indicating that Cmax should be the main  2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
48consideration for precision. Despi[INVESTIGATOR_268674], both 3000 mg 
single -dose studies indicated the variability  of Cmax approximately  40%, consistent with 
that of the 1500 mg single dose. Therefore, sample size justification for the 1500 mg 
single dose is also applicable for the 3000 mg dose.
Distance from 95% CI Upper Limit to t he Geometric Mean (given numbers 
of participant s exposed to the active dose)
n=10 n=12 n=15
AUC (0 -∞)
CV=21.5%16.4% 14.5% 12.5%
Cmax
CV=40.3%32.0% 28.0% 24.0%
CI = confidence interval ; CV = coefficient of variation .
9.3. Populations for A nalyses
For purposes of analy sis, the following populations are defined:
Population Description
Enrolled All participants who sign the ICF /assent .
Randomized All participants who are randomized.
Safety All participants who take at least [ADDRESS_326899]
evaluable postdose plasma concentration data for gepotidacin. This 
primary analysis population will be used in the assessment and 
characterization of PK concentrations (summary tables and figures).
PK ParameterAll pa rticipants in the PK population who received gepotidacin for
whom valid and evaluable plasma PK parameters are derived for 
gepotidacin. This primary analysis population will be used in the 
assessment and characterization of PK parameters (summary and 
analy sis tables and figures).
9.4. Statistical A nalyses
9.4.1. Pharmacokinetic A nalyses
Plasma and urine concentrations of gepotidacin will be subjected to PK analy ses using 
noncompartmental methods. Based on the individual gepotidacin concentration -time data 
the followi ng parameters will be estimated: 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
49Plasma:
AUC(0 -t) Area under the concentration- time curve from time 0 (predose) to 
time of the last quantifiable concentration
AUC(0 -∞) Area under the concentration- time curve from time 0 (predose) 
extrapolated to infinite time
AUC(0 -τ) Area under the concentration- time curve from time 0 (predose) to 
time tau ( tau = 12 and 6 for Part 1, Periods 2 and 3, respectivel y; 
for Part 2, tau will be between 6 and 12 )                          
AUC(0 -24) Area under the concentration- time curve from time 0 (predose) to 
[ADDRESS_326900] dose
AUC(0 -48) Area under the concentration- time curve from time 0 (predose) to 
[ADDRESS_326901] dose
Cmax Maximum observed conce ntration
Ro Accumulation ratio, calculated as:
Ro for AUC = AUC(0 -6) after second 3000 mg dose divided by  
[CONTACT_12265](0 -6) after the first 3000 mg dose
Ro for Cmax = Cmax after second [ADDRESS_326902] 3000 mg dose
t1/2 Terminal phase half-life
tlag Lag time before observation of drug concentrations in sampled 
matrix
Tmax Time to reach maximum observed plasma concentration
Urine:
Ae total Total unchanged drug (total amount of drug excreted in urine), 
calculated b y adding all the fra ctions of drug collected over all the 
allotted time intervals
Ae(t1 -t2) Amount of drug excreted in urine in time intervals of predose, 
0to2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 
12 to 24 hours, 24 to 36 hours, 36 to 48 hours, a nd 48 to 60 hours
(Period 2 and Period 3) after dosing
AUC(0 -τ) Area under the concentration- time curve from time 0 (predose) to 
time tau (tau = 12 and 6 for Part 1, Periods 2 and 3, respectivel y;  2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
50for Part 2, tau will be between 6 and 12)                          
AUC(0 -24) Area under the concentration- time curve from time 0 (predose) to 
24hours postdose administration following the first dose
AUC(0 -48) Area under the concentration- time curve from time 0 (predose) to 
[ADDRESS_326903] dose
fe% Percentage of the given dose of drug excreted in urine, calculated 
as:
fe% = (Ae total/Dose) × 100%
CLr Renal clearance of drug, calculated as: Ae total/AUC(0-t)
Plasma and urine concentrations of gepotidacin and the associated PK parameters will be 
listed, and summary  statistics (n, mean, median, standard deviation [ SD], minimum, 
maximum, and CV) will be presented b y Study Part and treatment. Mean and individual 
plasma concentration versus time profiles will be presented graphi cally on linear and 
semilogarithmic scales.
9.4.2. Safety  Analyses
All safet y anal yses will be performed on the Safety  Population. 
Safety  data will be presented in tabular format and summarized descriptively  according to 
[COMPANY_004]’s Integrated Data Standards Library  (IDSL) standards. No formal statistical analy sis 
of the safet y data will be conducted.
The details of the statistical anal yses of safety  and PK data will be provided in the 
reporting and anal ysis plan (RAP ).
9.4.3. Other A nalyses
Not applicable.
9.5. Interim Analyses
Preliminary  plasma PK and safet y results from participants in Part 1 will be reviewed b y 
the sponsor before enrolling participants into the next part of the study . The dosing 
interval to be used when two gepotidacin doses are given in Part 2, Period 2 willbe 
determined after a review of the PK and safet y results from Part 1. The number of PK 
samples and the PK sampling time points may  be modified based on the adult PK data 
from Part 1.
An ad hoc review of 12-lead ECG data may be performed between Part 1, P eriod 2 and 
Part 1, Period 3.
The RAP will describe the planned interim analy ses in greater detail. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
5110. SUPPORTING DOCUMENTA TION AND OPERA TIONAL
CONSIDERA TIONS
10.1. Appendix 1: A bbreviations and Trademarks
Abbrev iations
AChE acetylcholinesterase
AE adverse event
Ae total total unchanged drug
Ae(t1 -t2) amount of drug excreted in urine in a time interval
ALT alanine aminotransferase 
AUC area under the concentration -time curve
AUC(0 -∞) area under the concentration -time curve from time 0 (predose) 
extrapolated to infinite time
AUC(0 -24) area under the concentration -time curve from time 0 (predose) to 
[ADDRESS_326904] dose (plasma 
or urine)
AUC(0 -48) area under the concentration -time curve from time 0 (predose) to 
[ADDRESS_326905] dose (plasma 
or urine)
AUC(0 -t) area under the concentration -time curve from time [ADDRESS_326906] quantifiable concentration (plasma or urine)
AUC(0 -τ) area under the concentration -time curve from time 0 (predose) to 
time tau (plasma or urine)
BID twice daily
BMI body mass index
CA Competent Authorities
CFR Code of Federal Regulations
CIOMS Council for International Organizations of Medical Scienc es
CLr renal clearance of drug
Cmax maximum observed concentration
CONSORT Consolidated Standard of Reporting Trials
CV coefficient of variation
DMID Division of Microbiology and Infectious Diseases
DNA deoxyribonucleic acid
EC Ethics Committee
ECG electrocardiogram
eCRF electronic case report form
fe% percentage of the given dose of drug excreted in urine
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GI gastrointestinal
[COMPANY_004] GlaxoSmithKline
HDPE high-density polyethylene
HIPAA Health Insurance Portability and Accountability Act 2019N422403_00
2019N401 436_00 CONFIDENTIA L
[ADDRESS_326907]
IUD intrauterine device
IUS intrauterine hormone -releasing system
IV intravenous
MIC minimum inhibitory concentration
mm Hg millimeters of mercury
MSDS Material Safety Data Sheet
msec millisecond
NIAID National Institute of Allergy and Infectious Disease
PK pharmacokinetic
QTc corrected QT interval; the measure of time between the start of 
the Q wave and the end of the T wave
QTcB corrected QT interval using the Bazett formula
QTcF corrected QT interval using the Fridericia formula
RAP Reporting and Analysis Plan
Ro accumulation ratio
SAE serious adverse event
SD standard deviation
SoA schedule of activities
SRM Study Reference Manual
τ tau is the dosing interval in hours
t1/[ADDRESS_326908] infection
WOCPB women of childbearing potential
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_249233] 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
5310.2. Appendix 2: Clinical Laborator y Tests
The tests detailed in Table 10will be performed by  [CONTACT_12082] . 
Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 5of the protocol.
Additional tests may  be performed at an y time during the stud y as determined 
necessary  by [CONTACT_43215].
Pregnancy  Testing 
Refer to Section 5.1Inclusion Criteria for screening pregnancy  criteria.
Pregnancy  testing should be conducted at the time points indicated in the 
SoA ( see Section 1.3).
Additional serum or urine pregnancy  tests may  be performed, as determined 
necessary  by [CONTACT_268689], to establish the 
absence of pregnancy  at any  time during the participant's participation in the 
study .
Table 10 Protocol -Required Safety  Laboratory  Assessments
Laboratory 
AssessmentsParameters
Hematolog y
Platelet Count Red Blood Cell Indices:White blood cell count with 
differential:
Red Blood Cell Count Mean corpuscular volume Neutrophils
Hemoglobin Mean corpuscular hemoglobin Lymphocytes
Hematocrit Monocytes
Eosinophils
Basophils
Clinical Chemistry 1Blood urea nitrogen Aspartate aminotransferase Chloride
Creatinine Alanine aminotransferase Carbon dioxide
Glucose (fasting) Alkaline phosphatase Total protein
Potassium Total and direct bilirubin Albumin
Sodium Creatine phosphokina se
Magnesium Calcium
Routine Urinalysis Specific gravity
pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte 
esterase by [CONTACT_5230]
Microscopic examination (if blood, leukocyte esterase, or protein is abnormal) 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
54Laboratory 
AssessmentsParameters
Other S creening 
TestsSerology: HIV -1 and - 2 antigen/antibody immunoassay , Hepatitis B surface 
antigen (HBsAg), Hepatitis C (Hep C antibody)
Alcohol, cotinine, and drug screen (to include at minimum amphetamines, 
barbiturates, cocaine, opi[INVESTIGATOR_858], cannabinoids, and benzodiazepi[INVESTIGATOR_1651])
Pregnancy
Follicle -stimulating hormone
Fecal occult blood test and stool cultures as appropriate for gastrointestinal 
adverse events (Appendix 7).
1. Details of liver chemistry stoppi[INVESTIGATOR_268675] -up assessments after liver stoppi[INVESTIGATOR_43191] 7.1.1 andAppendix 6.All events of ALT [ADDRESS_326909] and bilirubin 2 × ULN 
(>35%  direct bilirubin) or ALT 3 × ULN and international normalized ratio (INR) >1.5, if INR measured, which 
may indicate severe liver injury (possible Hy’s Law), must be reported as an SAE (excluding studies of hepatic 
impairment or cirrhosis).
Laboratory  results that could unblind the s tudy will not be reported to the investigative 
siteor other blinded personnel until the study  has been unblinded. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
5510.3. Appendix 3: Regulatory , Ethical, and Study  Oversight 
Considerations
10.3.1. Regulatory  and Ethical Considerations
This study  will be conducted in acc ordance with the protocol and with:
Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines
Applicable International Council for Harmonisation ( ICH)Good Clinical 
Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF/assent form , Investigator Brochure, 
and other relevant documents ( e.g., advertisements) must be su bmitted to an 
IRB/IEC b y the investigator and reviewed and approved b y the IRB/IEC before 
the study  is initiated. 
Any amendments to the protocol will require IEC/I RB approval before 
implementation of changes made to the stud y design, except for changes 
necessary  to eliminate an immediate hazard to study participants. 
The investigator will be responsible for the following:
Providing written summaries of the status of the study to the IRB/IEC 
annually  or more frequently  in accordance with the requirements, policies, 
and procedures established by  [CONTACT_1201]/ IEC
Notify ing the IRB/IEC of SAE or other significant safet y findings as 
required b y IRB/IEC procedures
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 Code of Federal Regulations ( CFR ), ICH guidelines, 
the IRB/IEC, European regulation 536/2014 for clinical studies (if 
applicable), and all other applicable local regulations
10.3.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with suff icient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the stud y and for 1 y earafter completion of the study . 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
5610.3.3. Informed Consent /Assent Process
The investigator or his/her representative will explain the nature of the study to 
the participant or his/her legally  authorize d representative and answer all 
questions regarding the study . 
Participants must be informed that their participation is voluntary . Participants 
or their legall y authorized representative will be required to sign a statement of 
informed consent that meets the requirements of [ADDRESS_326910] (HI PAA) 
requirements, where applicable, and the IRB/IEC or study  center. 
The medical record must include a statement that written inform ed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent 
must also sign the I CF.
Participants must be re -consented to the most current versi on of the ICF(s) 
during their participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s 
legally  authorized representative. 
Adolescent participants should be asked for their written assent to participate in 
the study .
As applicable, the IRB will be consulted before assent form development for 
guidance around age -appropriate groupi[INVESTIGATOR_268676].
Participants who are rescreened are requ ired to sign a new ICF.
The I CF may  contain a separate section that addresses the use of remaining mandatory  
samples for optional exploratory  research in accordance with SOP- [COMPANY_004]F -410. The 
investigator or authorized designee will explain to each participant the objectives of the 
exploratory  research. Participants will be told that they  are free to refuse to participate 
and may  withdraw their consent at any  time and for an y reason during the storage period. 
A separate signature [CONTACT_22862] a participant's agreement to allow any  
remaining specimens to be used for exploratory  research. Participants who decline to 
participate will not p rovide this separate signature.
10.3.4. Data Protection
Participants will be assigned a unique identifier by  [CONTACT_456] . Any  participant 
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any  information which would make the participant 
identifiable will not be transferred. 
The participant must be informed that h is/her personal study -related data will be 
used by  [CONTACT_10999]. The level of 
disclosure must also be explained to the participant.  2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
57The participant must be informed that his/her medical records may  be examined 
by [CONTACT_17080] y Assurance auditors or other authorized personnel appointed 
by [CONTACT_456], b y appropriate IRB/IEC members, and by  [CONTACT_43216].
10.3.5. Publication Policy
The results of this study  may  be published or presented at scien tific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to 
the sponsor before submission. This allows the sponsor to protect proprietary  
information and to provide comments.
The sponsor will comply  with the requ irements for publication of study  results. 
In accordance with standard editorial and ethical practice, the sponsor will 
generall y support publication of multicenter studies only in their entiret y and not 
as individual site data. In this case, a coordinatin g investigator will be 
designated b y mutual agreement.
Authorship will be determined by  [CONTACT_43217].
10.3.6. Dissemination of Clinical Study  Data
Where required b y app licable regulatory  requirements, an investigator signatory  
will be identified for the approval of the clinical study  report. The investigator 
will be provided reasonable access to statistical tables, figures, and relevant 
reports and will have the opportun ity to review the complete study  results at a 
[COMPANY_004] site or other mutually -agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y 
results. The investigator is encouraged to share the summary  results with the 
study  participants , as appropriate.
[COMPANY_004] will provide the investigator with the randomization codes for their site 
only after completion of the full statistical anal ysis.
The procedures and timing for public disclosure of the protocol and results 
summary  and for devel opment of a manuscript for publication for this study  will 
be in accordance with [COMPANY_004] Policy .
[COMPANY_004] intends to make anony mized patient -level data from this trial available to 
external researchers for scientific anal yses or to conduct further research that 
canhelp advance medical science or improve patient care. This helps ensure the 
data provided b y trial participants are used to maximum effect in the creation of 
knowledge and understanding .
10.3.7. Data Quality  Assurance
All participant data relating to the stud y will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically  (e.g., 
laboratory  data). The investigator is responsible for verify ing that data entries 
are accurate and correct by  [CONTACT_268690].  2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
58The investigator must maintain accurate documentation (source data) that 
supports the information entered in the CRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory  agency  inspections and provide direct access to source data 
documents. 
Monitoring details describing strategy  (e.g., risk -based initiatives in operat ions 
and quality  such as Risk Management and Mitigation Strategies and Anal ytical 
Risk-Based Monitoring), methods, responsibilities and requirements, including 
handling of noncompliance issues and monitoring techniques (central, remote, 
or on -site monitoring) are provided in the Monitoring Plan.
The sponsor or designee is responsible for the data management of this study  
including qualit y checking of the data. 
The sponsor assumes accountability  for actions delegated to other individuals 
(e.g., contract research organizations).
Study  monitors will perform ongoing source data verification to confirm that 
data entered into the CRF b y authoriz ed site personnel are accurate, complete, 
and verifiable from source documents; that the safety  and rights of participants 
are being protected; and that the study is being conducted in accordance with the 
currentl y approved protocol and an y other stud y agreements, ICH GCP, and all 
applicable regulatory  requirements. 
Records and documents, including signed ICF /assent , pertaining to the conduct 
of this study  must be retained by  [CONTACT_1732] 25 y ears from the issue of 
the final clinical study report/e quivalent summary unless local regulations or 
institutional policies require a longer retention period. No records may  be 
destroy ed during the retention period without the written approval of the 
sponsor. No records may be transferred to another location o r part y without 
written notification to the sponsor. 
10.3.8. Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from 
source documents must be consistent with the source documents or the 
discrepancies must be explained. The investigator may  need to request previous 
medical records or transfer records, de pending on the study . Also, current 
medical records must be available.
Definition of what constitutes source data can be found in the SRM .
10.3.9. Study and Site Closure
[COMPANY_004] or its designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of [COMPANY_004]. Study  sites will be closed upon study   2019N422403_00
2019N401 436_00 CONFIDENTIA L
[ADDRESS_326911] been collected and a stud y-site closure visit has been performed.
The investigator may initiate study -site closure at any  time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include 
but are not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of participants by  [CONTACT_093]
Discontinuation of further study  intervention development 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
6010.4. Appendix 4: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
10.4.1. Definition of A E
AE Definition
An AE is an y untoward medical occurrence in a clinical study participant, temporally  
associated with the use of a study intervention, whether or not considered related to 
the study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments ( e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator ( i.e., not related 
to progression of underl ying disease).
Exacerbation of a chronic or inter mittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unles s it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.
Events NOT Meeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal s afety 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure ( e.g., endoscopy , appendectom y): the condition that  2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
61leads to the procedure is the AE.
Situations in which an untoward medical occur rence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.4.2. Definition of SA E
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , 
death due to progression of disease).
AnSAE is defined as any untoward medical occurrence that, at any dose:
oResults in death
oIs life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_42244]. If a 
complication prolongs hospi[INVESTIGATOR_268677], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from 
baseline is not considered an AE.
Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (e .g., sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
Is a c ongenital anomaly/birth defect
Other situations: 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
62Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or resul t in death or hospi[INVESTIGATOR_268678]. These events should usually  
be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse.
Cardiovascular and Gastrointestinal A dverse Events of Special Interest
Investigators will be required to fill out the specific cardiovascular or gastrointestinal 
event page of the eCRF for the following AEs and SAEs:
Cardiovascular Events: Gastrointestinal Events:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and 
transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  
embolism
Revasculariz ationNausea
Vomiting
Dysphagia
Abdominal pain
Diarrhea
Flatulence
Feces soft
Constipation
10.4.3. Recording and Follow -Up of A E and S AE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e .g.,hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports) 
related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s  2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
63medical re cords to [COMPANY_004] in lieu of completion of the [COMPANY_004] AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004]. In this case, all participant identifiers, with the exception of the 
participant number, will be re dacted on the copi[INVESTIGATOR_31785].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual sign s/symptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y according to the US National Institute of Allergy and Infectious 
Disease (NIAID) Division of Microbiology  and Infectious Diseases (DMID) criteria 
for adult toxicity  assessment ( see Appendix 8).
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A "reasonable possibility " of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y,and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the I nvestigator’s Brochure (IB) and/or Product 
Information, for markete d products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigat or has 
minimal information to include in the initial report to [COMPANY_004]. However, it is very 
important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to [COMPANY_004] .
The investigator may  chan ge his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory   2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
64reporting requirements.
Follow -up o f AE and SAE
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_31859]/or causality of the AE or SAE as fully as possible. This may  
include additional laboratory  tests or investigations, histopathological examinations, 
or consultation with other health care professionals.
If a participant dies during participation in the study or during a recognized follow -
up period, the investigator will provide [COMPANY_004] with a copy  of an y post-mortem 
findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within 24 hours of 
receipt of t he information.
10.4.4. Reporting of SA E to [COMPANY_004]
SAE Reporting to [COMPANY_004] via Electronic Data Collection Tool
The primary  mechanism for reporting SAE to [COMPANY_004] will be the electronic data 
collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
The investigator or medically -qualified sub -investigator must s how evidence within 
the eCRF (e.g., check review box, signature, etc.) of review and verification of the 
relationship of each SAE to I P/study  participation (causalit y) within 72 hours of SAE 
entry  into the eCRF.
After the stud y is completed at a given site , the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the ele ctronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to the medical monitor by [CONTACT_756].
Contacts for SAE reporting can be found in SRM .
SAE Reporting to [COMPANY_004] via Paper CRF
Facsimile transmission of the SAE paper CRF is the preferred method to transmit  2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
65this information to the medical monitor.
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE da ta collection tool sent by  [CONTACT_19515].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting c an be found in SRM . 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
6610.5. Appendix 5: Contraceptive Guidance and Collection of 
Pregnancy  Information
10.5.1. Definitions:
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanentl y sterile (see below).
If fertility  is unclear ( e.g., amenorrhea in adolescents or athl etes) and a menstrual cy cle 
cannot be confirmed before first dose of stud y intervention, additional evaluation should 
be considered.
Women in the following categories are not considered WOCBP
1.Premenarchal
2.Premenopausal female with 1 of the following:
Documented h ysterectomy
Documented bilateral salpi[INVESTIGATOR_1656]
Documented bilateral oophorectom y
For individuals with permanent infertility  due to an alternate medical cause other 
than the above, ( e.g., müllerian agenesis, androgen insensitivity ), investigator 
discretion should be applied to determining stud y entry .
Note: Documentation can come from the site personnel’s review of the 
participant’s medical records, medical examination, or medical history  interview.
3.Postmenopausal female
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. 
A high follicle -stimulating hormone (FSH) level in the postmenopausal 
range may  be used to confirm a pos tmenopausal state in women not 
using hormonal contraception or hormonal replacement therap y (HRT). 
However, in the absence of 12 months of amenorrhea, confirmation with 
more than one FSH measurement (>40 IU/L or mIU/mL ) is required. 
Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non -estrogen hormonal highl y effective contraception methods 
if they  wish to continue their HRT during the study . Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopaus al status before 
study  enrollment. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
6710.5.2. Contraception Guidance:
 CONTRACEPTIVESaALLOWED DURING THE STUDY INCLUDE:
 Highly Effective MethodsbThat Have Low User Dependency Failure rate of <1% per year 
when used consistently and correctly.
 Implantable progestoge n-only hormone contraception associated with inhibition of ovulationb
 Intrauterine device (IUD)
 Intrauterine hormone -releasing system (IUS) b
 Bilateral tubal occlusion
 Vasectomized partner
Note: Vasectomized partner is a highly effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the absence 
of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used. Spermatogenesis cycle is approxim ately 90 days .
 Highly Effective MethodsbThat Are User Dependent Failure rate of <1%  per year when 
used consistently and correctly.
 Combined (estrogen -and progestogen -containing) hormonal contraception associated with 
inhibition of ovulationc
oral
intravaginal
transdermal
injectable
 Progestogen -only hormone contraception associated with inhibition of ovulationc
oral
injectable
 Sexual abstinence
Note : Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexu al intercourse during the entire period of risk associated with 
the study intervention. The reliability of sexual abstinence needs to be evaluated in 
relation to the duration of the study and the preferred and usual lifestyle of the 
participant.
 ACCEPTABL E METHODSd
 Progestogen -only oral hormonal contraception where inhibition of ovulation is not the primary 
mode of action
 Male or female condom with or without spermicidee
 Cervical cap, diaphragm, or sponge with spermicide
 A combination of male condom wi th either cervical cap, diaphragm, or sponge with spermicide 
(double -barrier methods)c 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
68a. Contraceptive use by [CONTACT_103092].
b. Failure rate of <1%  per year when used consistently and correctly. Typi[INVESTIGATOR_159831].
c. If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable contr aceptive 
methods are limited to those which inhibit ovulation as the primary mode of action.
d. Considered effective, but not highly effective -failure rate of ≥1%  per year.  Periodic abstinence (calendar, 
sympto -thermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational 
amenorrhoea method (LAM) are not acceptable methods of contraception.
e. Male condom and female condom should not be used together (due to risk of failure with friction).
10.5.3. Collection of Pregnancy  Informa tion:
Male participants with partners who become pregnant
Investigator will attempt to collect pregnancy  information on any  male participant’s 
female partner of a male study  participant who becomes pregnant while participating 
in this study . This applies only  to male participants who receive gepotidacin .
After obtaining the necessary  signed informed consent from the pregnant female 
partner directl y, the investigator will record pregnancy information on the 
appropriate form and submit it to [COMPANY_004] within 24 hou rsoflearning of the partner’s 
pregnancy . 
The female partner will also be followed to determine the outcome of the pregnancy . 
Information on the status of the mother and child will be forwarded to [COMPANY_004].
Generally , follow -up will be no longer than 6 to 8 w eeks following the estimated
delivery  date. An y termination of the pregnancy  will be reported regardless of fetal 
status (presence or absence of anomalies) or indication for procedure. 
Female Participants who become pregnant
Investigator will collect preg nancy  information on any  female participant who 
becomes pregnant while participating in this study. 
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within 
24 hours of learning of a participant's pregnancy . 
Participant will be fo llowed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on participant and neonate, which will 
be forwarded to [COMPANY_004] .Generall y, follow -up will not be required for longer than 6 to 
8weeks bey ond the estimated de livery  date.  
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure. 
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective te rmination of a pregnancy for medical reasons will be 
reported as an AE or SAE. 
A spontaneous abortion (occurring at <22 weeks gestational age) or still birth 
(occurring at >22 weeks gestational age) is always considered to be an SAE and will 
be reported a s such.  2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
69Any SAE occurring as a result of a post -study  pregnancy which is considered 
reasonabl y related to the study  intervention b y the investigator, will be reported to 
[COMPANY_004] as described in Appendix 4. While the investigator is not o bligated to activel y 
seek this information in former stud y participants, he or she may learn of an SAE 
through spontaneous reporting. 
Any female participant who becomes pregnant while participating will be withdrawn 
from the study . 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
7010.6. Appendix 6: Liver Safet y: Required A ctions and Follow -up 
Assessments
Phase I liver chemistry stoppi[INVESTIGATOR_227525]- absoluteALT≥3xULN
If ALT ≥3xULN AND bilirubin1,22xULN (>35% direct bilirubin) or INR>1.5, 
Report as an SAE.
See additional Actions and Follow Up Assessments listed below
Required Actions and Follow up Assessments 
Actions Follow Up Assessments
Immediately discontinue study intervention
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF, and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the participant until liver chemistries 
resolve, stabilize, or return to within baseline 
(see MONITORING below)
MONITORING:
If ALT ≥3xULN AND bilirubin 2xULN or INR 
>1.5
Repeat liver chemistries (include ALT, 
aspartate transaminase [AST ], alkaline 
phosphatase, bilirubin and INR) and perform 
liver event follow up assessments within 24 
hours
Monitor participant twice weekly until liver 
chemistries resolve, stabili ze,or return to 
within baseline
A specialist or hepatology consultation is 
recommended
If ALT ≥3xULN AND bilirubin < 2xULN and INR Viral hepatitis serology3
Obtain international normalized ratio (INR)
and recheck with each liver chemistry 
assessment until the transaminases values 
show downward trend
Obtain blood sample for pharmacokinetic 
(PK) analysis, obtained within [ADDRESS_326912] dose4 
Serum creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH)
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medicati ons on 
the concomitant medications report form 
including acetaminophen, herbal remedies, 
other over the counter medications.
Record alcohol use on the liver event 
alcohol intake case report form
If ALT ≥3xULN AND bilirubin 2xULN or INR  2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
71Liver Chemistry Stoppi[INVESTIGATOR_2121] 
≤1.5:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin, and I NR) and 
perform liver event follow up assessments 
within 24-72 hours
Monitor participant weekly until liver 
chemistries resolve, stabilize, or return to 
within baseline>1.5 :
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti- liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG) or gamma 
globulins.
Liver imaging (ultrasound, magnetic 
resona nce, or computeri zed tomography) 
and /or liver biopsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy CRF forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immed iately available, discontinue study intervention for that participant if ALT 3xULN and bilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary bilirubin on 
dipstick, indicating direc t bilirubin elevations and suggesting liver injury.
2. All events of ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN and INR>1.5, which 
may indicate severe liver injury (possible “Hy’s Law ”), must be reported as an SAE (excluding stud ies of hepatic 
impairment or cirrhosis); the INR threshold value stated will not apply to participant s receiving anticoagulants.
3. Includes: Hepatitis A immunoglobulin ( IgM) antibody; HBsAg and HBcAb; Hepatitis C RNA; Cytomegalovirus IgM 
antibody; Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain heterophile antibody or 
monospot testing) ,and Hepatitis E IgM antibody.
4. PK sample may not be required for participants known to be receiving placebo or non -[COMPANY_004] comparator 
interventions.  Reco rd the date/time of the PK blood sample draw and the date/time of the last dose of study 
intervention prior to PK blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the 
participant’s best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot 
be collected in the time period indicated above, do not obtain a PK sample. Instructions for sample handling and 
shippi[INVESTIGATOR_268679] M. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
7210.7. Appendix 7: Clostridium difficile Testing Procedure and 
Algorithm
Note:  This algorithm is subject to investigator discretion when the clinical 
presentation and time course of diarrhea (e.g., during or within 12 hours immediately 
after dosing) do not fit the Clostridium difficile associated diarrhea definitio n; 
consideration should be given to diarrhea occurring in this early time frame to be 
suggestive of a cholinergic effect. 2019N422403_00
2019N401 436_00 CONFIDENTIA L
2096 11
7310.8. Appendix 8: Division of Microbiology  and Infectious 
Diseases A dult Toxicity  Tables for A dverse Event 
Assessment
ESTIMATING SEVERITY GR ADE: For abnormalities NOT found elsewhere in the 
Toxicity  Tables, use the scale below to estimate grade of severit y:
GRADE 1 MildTransient or mild discomfort (<48 hours); no medical 
intervention/therapy required
GRADE 2 ModerateMild to moderate limitat ion in activity –some assistance may 
be needed; no or minimal medical intervention/therapy 
required
GRADE 3 SevereMarked limitation in activity, some assistance usually 
required; medical intervention/therapy required, 
hospi[INVESTIGATOR_249212] 4 Life-threateningExtreme limitation in activity, significant assistance required; 
significant medical intervention/therapy required, 
hospi[INVESTIGATOR_249213] -THREATENING AEs: ANY clinical event deemed by  [CONTACT_1275] t o be serious or life -threatening should be considered a Grade 4 event. 
Clinical events considered to be serious or life -threatening include, but are not limited to,
seizures, coma, tetan y, diabetic ketoacidosis, disseminated intravascular coagulation, 
diffuse petechiae, paral ysis, acute ps ychosis, and severe depression.
COMMENTS REGARDING THE USE OF THESE TABLES
Standardized and commonly  used toxicity  tables (Division of AIDS, National Cancer 
Institute’s Common Toxicity  Criteria, and World Health Organizati on) have been 
adapted for use b y the Division of Microbiology and I nfectious Diseases (DAIDS) 
and modified to better meet the needs of participants in Division of Microbiology  and 
Infectious Diseases (DMID) trials (November 2007) .
For parameters not includ ed in the following Toxicity  Tables, study  sites should refer 
to the “Guide for Estimating Severit y Grade” located above.
Criteria are generall y grouped by  [CONTACT_44749]. 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
74HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hemoglobin 9.5 to 10.5 gm/dL 8.0 to 9.4 gm/dL 6.5 to 7.9 gm/dL <6.5 gm/dL
Absolute Neutrophil Count 1000 to 1500 /mm3 750 to 999 /mm3` 500 to 749 /mm3 <500 /mm3
Platelets 75,000 to 99,999 /mm3 50,000 to 74,999 /mm3 20,000 to 49,999 /mm3 <20,000 /mm3
White Blood Cells 11,000 to 13,000 /mm3 13,000 to 15,000 /mm3 15,000 to 30,000 /mm3 >30,000 or <1000 /mm3
% Polymorphonuclear Leukocytes + 
Band Cells>80% 90 to 95% >95% N/A
Abnormal FibrinogenLow: 100 to 200 mg/dL
High: 400 to 600 mg/dLLow: <100 mg/dL
High: >600 mg/dLLow: <50 mg/dL
High: N/AFibrinogen associated with gross bleeding or 
with disseminated coagulation
Fibrin Split Product 20 to 40 mcg/mL 41 to 50 mcg/mL 51 to 60 mcg/dL >60mcg/dL
Prothrombin Time (PT) 1.01 to 1.25 ULN 1.26 to 1.5 ULN 1.51 to 3.0 ULN >3ULN
Activated P artial Thromboplastin (APTT) 1.01 to 1.66 ULN 1.67 to 2.33 ULN 2.34 to 3 ULN >3ULN
Methemoglobin 5.0 to 9.9% 10.0 to 14.9% 15.0 to 19.9% >20%
N/A=not applicable; ULN=upper limit of normal.  
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
75CHEMISTRIES
Grade 1 Grade 2 Grade 3 Grade 4
Hypona tremia 130 to 135 mEq/L 123 to 129 mEq/L 116 to 122 mEq/L<116 mEq/L or abnormal sodium withmental 
status changes or seizures
Hypernatremia 146 to 150 mEq/L 151 to 157 mEq/L 158 to 165 mEq/L>165 mEq/L or abnormal sodium withmental 
status changes or sei zures
Hypokalemia 3.0 to 3.4 mEq/L 2.5 to 2.9 mEq/L2.0 to 2.4 mEq/L or intensive 
replacement therapy of 
hospi[INVESTIGATOR_91536]<2.0 mEq/L or abnormal potassium with
paresis, ileus, or life -threatening arrhythmia
Hyperkalemia 5.6 to 6.0 mEq/L 6.1 to 6.5 mEq/L 6.6 to 7.0 mEq/L>7.0 mEq/L or abnormal potassium with
life-threatening arrhythmia
Hypoglycemia 55 to 64 mg/dL 40 to 54 mg/dL 30 to 39 mg/dL<30mg/dL or abnormal glucose withmental 
status changes or coma
Hyperglycemia
(nonfasting and no prior 
diabetes)116 to 160 mg/dL 161 to 250 mg/dL 251 to 500 mg/dL>500 mg/dL or abnormal glucose with
ketoacidosis or seizures
Hypocalcemia
(corrected for albumin)8.4 to 7.8 mg/dL 7.7 to 7.0 mg/dL 6.9 to 6.1 mg/dL<6.1 mg/dL or abnormal calcium with
life-threatening arrhythmia or tetany
Hypercalcemia
(corrected for albumin)10.6 to 11.5 mg/dL 11.6 to 12.5 mg/dL 12.6 to 13.5 mg/dL>13.5 mg/dL or abnormal calcium with
life-threatening arrhythmia
Hypomagnesemia 1.4 to 1.2 mEq/L 1.1 to 0.9 mEq/L 0.8 to 0.6 mEq/L<0.6 mEq/L or abnormal magnesium with
life-threatening arrhythmia
Hypophosphatemia 2.0 to 2.4 mg/dL1.5 to 1.9 mg/dL or 
replacement Rx required1.0 to 1.4 mg/dL
intensive therapy or hospi[INVESTIGATOR_126693]<1.0 mg/dL or abnormal phosphate with
life-threatening arrhythmia
Hyperbilirubinemia (when 
accompanied by [CONTACT_126746])1.1 to <1.25 ULN 1.25 to <1.5 ULN 1.5 to 1.75 ULN >1.75 ULN
Hyperbilirubinemia (when other 
liver function tests are in the 
normal range)1.1 to < 1.5ULN 1.5 to <2.0 ULN 2.0 to 3.0 ULN >3.0ULN
Blood urea nitrogen 1.25 to 2.5 ULN 2.6 to 5 ULN 5.1 to 10 ULN >10ULN
Hyperuricemia (uric acid) 7.5 to 10.0 mg/dL 10.1 to 12.0 mg/dL 12.1 to 15.0 mg/dL >15.0 mg/dL
Creatinine 1.1 to 1.5 ULN 1.6 to 3.0 ULN 3.1 to 6.0 ULN >6ULN or dialysis required
Rx=therapy; ULN=upper limit of normal. 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
76ENZYMES
Grade 1 Grade 2 Grade 3 Grade 4
Aspartate aminotransferase (AST) 1.1 to <2.0 ULN 2.0 to <3.0 ULN 3.0 to 8.0 ULN >8.0ULN
Alani ne aminotransferase (ALT) 1.1 to <2.0 ULN 2.0 to <3.0 ULN 3.0 to 8.0 ULN >8.0ULN
Gamma to glutamyl transferase (GGT) 1.1 to <2.0 ULN 2.0 to <3.0 ULN 3.0 to 8.0 ULN >8.0ULN
Alkaline Phosphatase 1.1 to <2.0 ULN 2.0 to <3.0 ULN 3.0 to 8.0 ULN >8.0ULN
Amylase 1.1 to 1.5 ULN 1.6 to 2.0 ULN 2.1 to 5.0 ULN >5.1ULN
Lipase 1.1 to 1.5 ULN 1.6 to 2.0 ULN 2.1 to 5.0 ULN >5.1ULN
ULN=upper limit of normal.
URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Proteinuria1+ or
200mg to 1 gm loss/day2 to 3+ or
1 to 2 gm loss/day4+ or
2 to 3.5 gm loss/dayNephrotic syndrome or
>3.5 gm loss/day
HematuriaMicroscopic only
<10RBC/ HPFGross, no clots
>10RBC/ HPFGross, with or without clots,
or red blood cells castsObstructive or
required transfusion
HPF=high powered field; RBC=red blood cells. 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
77CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac rhythmN/A Asymptomatic, transient signs, no 
Rx requiredRecurrent/persistent; symptomatic 
Rx requiredUnstable dysrhythmia; 
hospi[INVESTIGATOR_249214] >20 mm/Hg;
no treatment Recurrent, chronic increase 
>20mm/Hg;
treatment required Acute treatment required; 
outpatient treatment or 
hospi[INVESTIGATOR_268680] 
<20beat/min or decreased by 
<10mmHg systolic BP.
No treatment requiredSymptoms due to orthostatic 
hypotension or BP decreased by 
<20mmHg systolic; correctab le with 
oral fluid treatmentRequires IV fluids;
no hospi[INVESTIGATOR_249216] <60 mmHg 
or end organ damage or shock;
requires hospi[INVESTIGATOR_268681]/moderate asymptomatic 
effusion , no treatmentSymptomatic effusion; pain; EKG 
changesTamponade; pericardiocentesis or 
surgery required
Hemorrhage, Blood Loss Microscopic/occult Mild, no transfusion Gross blood loss; 
1 to 2 units transfusedMassive blood loss; >3 units 
transfused
BP=blood pressure; IV=intravenous; EKG=electrocardiogram; N/A=not applicable; Rx=therapy.
RESPI[INVESTIGATOR_10806] 1 Grade 2 Grade 3 Grade 4
CoughTransient; no treatment Persistent cough; treatment 
responsiveParoxysmal cough; uncontrolled 
with treatmentN/A
Bronchospasm, AcuteTransient; no treatment; FEV 170 
to 80% of peak flowRequires treatment; normalizes with 
bronchodilator; FEV 150 to 70 % of 
peak flowNo normalization with 
bronchodilator; FEV 125 to 50 % of 
peak flow; or retractions presentCyanosis: FEV 1<25%  of peak flow; 
or intubation necessary
Dyspnea Dyspnea on exertion Dyspnea with normal activity Dyspnea at rest Dyspnea requiring oxygen therapy
FEV 1=forced expi[INVESTIGATOR_3741] 1 second; N/A=not applicable. 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
78GASTROINTESTINAL
Grade 1 Grade 2 Grad e3 Grade 4
NauseaMild or transient; 
maintains reasonable 
intakeModerate discomfort; intake 
decreased significantly; some 
activity limitedNo significant intake; requires IV fluids Hospi[INVESTIGATOR_249217]1 epi[INVESTIGATOR_85712] 24 hours 2 to 5 epi[INVESTIGATOR_11630] 24 hours >6 epi[INVESTIGATOR_11630] 24 hours or needing IV 
fluidsPhysiologic consequences requiring 
hospi[INVESTIGATOR_268682] e vacuation 
or enemaObstruction or toxic megacolon
DiarrheaMild or transient; 3 to 
4loose stools/day or mild 
diarrhea lasting <1 weekModerate or persistent; 5 to 
7loose stools/day or diarrhea 
lasting >1 week>7 loose stools/day or bloody diarrhea; or 
orthostatic hypotension or electrolyte 
imbalance or >2L IV fluids requiredHypotensive shock or physiologic 
consequences requiring hospi[INVESTIGATOR_268683]/
DysphagiaMild discomfort; no 
difficulty swallowingSome limits on eating/drinking Eating/ta lking very limited; unable to 
swallow solid foodsUnable to drink fluids; requires IV fluids
IV=intravenous.
NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Neuro- CerebellarSlight incoordination 
dysdiadochokinesisIntention tremor, dysmetria, 
slurred sp eech; nystagmusLocomotor ataxia Incapacitated
PsychiatricMild anxiety or depression Moderate anxiety or depression; 
therapy required; change in 
normal routineSevere mood changes requiring therapy; 
or suicidal ideation; or aggressive 
ideationAcute psyc hosis requiring 
hospi[INVESTIGATOR_059]; or suicidal 
gesture/attempt or hallucinations
Muscle strengthSubjective weakness; no 
objective symptoms/signsMild objective signs/symptoms; no 
decrease in functionObjective weakness; function limited Paralysis
Paresthe sia
(burning, tingling, etc.)Mild discomfort; no treatment 
requiredModerate discomfort; non -narcotic 
analgesia requiredSevere discomfort; or narcotic analgesia 
required with symptomatic improvementIncapacitating; or not responsive 
to narcotic analgesia
NeurosensoryMild impairment in sensation 
(decreased sensation, e.g., 
vibratory, pi[INVESTIGATOR_29107], hot/cold in 
great toes) in focal area or 
symmetrical distribution; or 
change in taste, smell, vision, 
and/or hearingModerate impairment (moderately 
decreased sensation, e.g., 
vibratory, pi[INVESTIGATOR_29107], hot/cold to 
ankles) and/or joint position or 
mild impairment that is not 
symmetricalSevere impairment (decreased or loss of 
sensation to knees or wrists) or loss of 
sensation of at least moderate degree in 
multiple differ ent body areas (i.e., upper 
and lower extremities)Sensory loss involves limbs and 
trunk; paralysis; or seizures 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
2096 11
79MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia (joint 
pain)Mild pain not interfering with function Moderate pain, analgesics a nd/or pain 
interfering with function but not with ADLSevere paid; pain and/or analgesics 
interfering with ADLDisabling pain
ArthritisMild pain with inflammation, erythema or 
joint swelling, but not interfering with 
functionModerate pain with inflammat ion, erythema or 
joint swelling; interfering with function but not 
with ADLSevere pain with inflammation, 
erythema or joint swelling, and 
interfering with ADLPermanent and/or 
disabling joint 
destruction
MyalgiaMyalgia with no limitation of activity Muscle tenderness (at other than injection site) 
or with moderate impairment of activitySevere muscle tenderness with marked 
impairment of activityFrank myonecrosis
ADL=activities of daily living.
SKIN
Grade 1 Grade 2 Grade 3 Grade 4
MucocutaneousErythema; pruritus Diffuse, maculo papular rash, dry 
desquamationVesiculation or moist 
desquamation or ulcerationExfoliative dermatitis, mucous membrane 
involvement or erythema, multiforme or suspected 
Stevens- Johnson or necrosis requiring surgery
Induratio n <15mm 15 to 30 mm >30mm N/A
Erythema <15mm 15 to 30 mm >30mm N/A
Edema <15mm 15 to 30 mm >30mm N/A
Rash at injection site <15mm 15 to 30 mm >30mm N/A
Pruritus Slight itching at injection site Moderate itching at injection extremity Itching ov er entire body N/A
N/A=not applicable.
SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Allergic reaction Pruritus without rash Localized urticarial Generalized urticarial; angioedema Anaphylaxis
HeadacheMild, no treatment required Transient, moderate; treat ment 
requiredSevere; responds to initial narcotic 
therapyIntractable; requires repeated 
narcotic therapy
Fever: oral 37.7 to 38.5 C or 100.0 to 101.5 F 38.6 to 39.5 C or 101.6 to 102.9 F 39.6 to 40.5 C or 103 to 105 F >40 C or >105 F
FatigueNormal act ivity reduced <48 hours Normal activity decreased 25 to 50%; 
>48 hoursNormal activity decreased >50 %; 
cannot workUnable to care for self 
 
 2019N422403_00
2019N401436_00 CONFIDENTIA L
[ADDRESS_326913], Gorrec F, et al. Ty pe IIA
topoisomerase inhibit ion by  a new class of antibacterial agents. Nature .
2010;466(7309):935-40.
GlaxoSmithKline Document Number 2014N198291_00 Study  ID BTZ115198. A two 
part study  to evaluate safety , tolerability , and pharmacokinetics of single and repeat IV 
doses of [COMPANY_004]214094 4 in healthy  adult subjects. 2014.
GlaxoSmithKline Document Number 2015N227098_00 Study  ID BTZ115775: 
Population pharmacokinetic -pharmacod ynamic analy sis of a Phase I, randomized, 
double -blinded, placebo -and moxifloxacin -controlled, [ADDRESS_326914] of [COMPANY_004]2140944 on cardiac conduction as assessed b y 12-lead 
electrocardiogram in healthy  volunteers. 2015.
GlaxoSmithKline Document Number 2015N243789_00 Study  ID BTZ116704. A 
Phase II, randomized, two -part, multicenter, dose -rangi ng stud y in adult subjects 
evaluating the safet y, tolerability, and efficacy of [COMPANY_004]2140944 in the treatment of 
subjects with suspected or confirmed gram -positive acute bacterial skin and skin structure 
infections. 2015.
GlaxoSmithKline Document Number CM20 10/[ZIP_CODE]/ 06. Gepotidacin Investigator’s 
Brochure. 2019. 2019N422403_00